Biomarkers for lymphoma

ABSTRACT

A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin&#39;s lymphoma or non-Hodgkin&#39;s lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application Ser. No. 61/565,036, filed Nov. 30, 2011, titled “BIOMARKERS FOR HODGKIN'S LYMPHOMA”, and International Application No. PCT/US2012/057935, filed Sep. 28, 2012, titled “BIOMARKERS FOR LYMPHOMA”, hereby incorporated by reference in their entirety for all of their teachings.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

The invention was made with Government support under Contract DE-AC05-76RLO1830, awarded by the U.S. Department of Energy. The Government has certain rights in the invention.

TECHNICAL FIELD

This invention relates to biomarkers for lymphoma. More specifically, this invention relates to plasma biomarkers for detecting Hodgkin's lymphoma or non-Hodgkin's lymphoma.

BACKGROUND OF THE INVENTION

In the presence of human immunodeficiency virus (HIV) infection, non-Hodgkin's lymphoma (NHL) and Kaposi sarcoma (KS) were the first malignancies used to define acquired immune deficiency syndrome (AIDS). People with HIV infection are also at increased risk of a number of other cancers. As people with HIV infection live longer due to highly active antiretroviral therapy (HAART), the incidence of these non-AIDS-defining cancers has increased among HIV-infected individuals. One of the most common of these malignancies is Hodgkin's lymphoma (HL), and it has been estimated that people with HIV/AIDS have a 5.6- to 14.7-fold increased risk of developing HL compared to the general population.

HL is a solid tumor that is comprised of no more than 2% of the cancerous B lymphocytes. Instead, these lymphocytes secrete a wide range of cytokines that attract numerous normal leukocytes that then comprise the large majority of the tumor. Thus, HL is largely seen as an uncontrolled inflammatory disease. In people with immunosuppression, HL is believed to result from the Epstein-Barr virus (EBV). EBV is present in nearly all adults, but typically only causes HL when the immune system is suppressed, such as with HIV infection.

The increase in non-AIDS-defining cancers has created a greater need for the early detection of these malignancies in this susceptible population. It seems likely that HIV-infected individuals would benefit from a routine, non-invasive screen for HL, but no such screen exists. Rather, HL patients are identified after they become symptomatic. Chemotherapy and radiation therapy have been shown to be very effective at causing HL remission, but morbidity and mortality associated with these treatments is substantial. Early-stage HL is generally treated less intensively, suggesting that early detection of HL would result in less treatment-related toxicity. Cancer treatment strategies for HIV-infected individuals with HL are the same as for non-AIDS subject, but HIV-infected patients require additional vigorous supportive care (HAART, antifungals, neutrophil-simulating growth factors).

What is needed is a blood-based test to detect lymphoma earlier, when the tumor burden is much smaller, which would allow for less severe therapy and reduce long-term mortality and morbidity associated with current treatments.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, a biomarker for detecting lymphoma in a person is disclosed. The biomarkers include at least one protein listed in Table S3.

The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The at least one protein is found in plasma, and the person is a high-risk subject.

In another embodiment of the present invention, a method of detecting lymphoma in a person is disclosed. The method includes obtaining a plasma sample from the person. The method further includes measuring the level of at least one protein listed in Table S3 in the plasma sample. The method also includes comparing the level of the at least one protein in the plasma sample with the level in a normal or healthy subject; and diagnosing the lymphoma based upon the level of the at least one protein in the plasma sample in comparison to the normal level. In one embodiment, the obtaining a plasma sample from the person further comprises providing a reagent that reacts with proteins in the plasma sample to detect the presence of lymphoma. The reagent may be an antibody.

In another embodiment of the present invention, a test kit for diagnosing lymphoma in a person is disclosed. The test kit includes an antibody-based assay that measures a plurality of plasma biomarkers selected from the group consisting of the biomarkers of Table S3; and instructions for conducting the antibody-based assay.

In another embodiment of the present invention, a diagnostic system for detecting the presence of lymphoma in a person is disclosed. The system includes a plurality of protein assays measuring a plurality of plasma biomarkers. The plasma biomarkers are selected from the biomarkers of Table S3. Concentration levels or peak intensity values of at least one of the plasma biomarkers is modified by the presence of the lymphoma in the person. The system also includes a detector for detecting the plasma biomarkers.

In one embodiment, the detector is a mass spectrometer. In another embodiment, the detector includes at least one labeled antibody specific for a biomarker of Table S3.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to methods, diagnostic systems, kits, and biomarkers for detecting lymphoma in a patient. These biomarkers may form the basis for a blood-based test for early detection of lymphoma and may be used clinically.

To identify candidate biomarkers for Hodgkin's Lymphoma (HL) detection, plasma samples from HIV-infected patients were analyzed, with or without HL, using accurate mass tag and time (AMT) tag proteomics, and thereby identified a set of 60 proteins. As a group, these proteins are associated with both cancer and inflammation and therefore are promising candidate biomarkers for early detection of HL.

Materials and Methods

Ethics Statement.

The study protocol was approved by the George Washington University Medical Center Institutional Review Board. Written informed consent was obtained from all study participants. Additional approval from the PNNL Institutional Review Board, which included a review of the George Washington University Medical Center IRB approval, was obtained before samples were transferred to PNNL.

Human Subjects and Sample Processing.

-   -   Frozen, human plasma samples were provided by the AIDS and         Cancer Specimen Resource (San Francisco, Calif.). The control         subjects (HIV-infected without HL) were chosen to approximately         match the cases (HIV-infected with HL) based on gender and age         (Table 1). In most cases, plasma samples were collected from         HIV-infected subjects with HL that had not received HL         chemotherapy within at least 30 days (n=12). Information on         chemotherapy was unknown for some cases (n=9) and one sample was         known to have been collected within 30 days of chemotherapy. For         all processing and analytical steps, samples were blocked based         on HL status and randomized. The 12 most abundant plasma         proteins were depleted using the Proteome Purify™ 12         immunodepletion resin (R&D Systems), according to the         manufacturer's protocol. The remaining plasma proteins were         precipitated using ice-cold trichloroacetic acid at a final         concentration of 10%, followed by overnight incubation at 4° C.         and centrifugation at 14,000×g for 5 minutes. The pellet was         washed with cold acetone and dried at room temperature for 5         minutes prior to suspension in 25 μL of 100 mM ammonium         bicarbonate, 8 M urea, 2 M thiourea and 5 mM dithiothreitol, and         heating to 60° C. for 30 min. The samples were then diluted         4-fold with 100 mM ammonium bicarbonate and CaCl₂ was added to 1         mM. Methylated, sequencing-grade trypsin (Promega, Madison,         Wis.) was added at a substrate-to-enzyme ratio of 50:1         (mass:mass) and incubated at 37° C. for 15 h. Peptides were then         purified by binding to a 1 mL SPE C₁₈ column (Supelco,         Bellefonte, Pa.) and eluting with 1 mL of methanol. After         concentration in a SpeedVac, the samples were dissolved in 25 mM         ammonium bicarbonate and frozen at −20° C. until analysis.

TABLE 1 Subject characteristics. HIV+ HIV+/HL+ Number 14 22 Gender (M/F) 10/4 20/2 Age (min-max) 53.9 ± 5.9^(a) (42-63) 49.2 ± 8.8 (34-66) CD4 count^(b) 404 ± 380 203 ± 224 CD4 count < 200^(c) 4 (29%) 12 (55%) HAART^(d) (yes, no, 12, 1, 1 11, 4, 7 unknown) Lymph node NA^(e)  6 involvement ^(a)Mean ± standard deviation. ^(b)Units are CD4-positive cell counts per μL blood. ^(c)CD4 counts of less than 200/μL has been used to define the presence of AIDS in HIV positive subjects. ^(d)Indicates current usage of HAART antiretroviral therapy at the time of the blood draw. “Unknown” indicates that HAART usage at the time of the blood draw is unknown. Prior usage is unknown for all subjects. ^(e)NA, not applicable.

Liquid Chromatography-Mass Spectrometry.

Peptide samples were analyzed using a custom-built, automated, high-pressure nanocapillary liquid chromatography (HPLC) system coupled on-line to a LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific). The reversed-phase capillary column was prepared by slurry packing 3-μm Jupiter C18 bonded particles (Phenomenex, Torrence, Calif.) into a 65-cm-long, 75-μm-inner diameter fused silica capillary (Polymicron Technologies, Phoenix, Ariz.). The mobile phase consisted of 0.2% acetic acid and 0.05% trifluoroacetate in water (A) and 0.1% trifluoroacetate in 90% acetonitrile, 10% water (B). After loading 5 μL (2.5 μg total) of peptides onto the column, the mobile phase was held at 100% A for 50 min. Exponential gradient elution was performed by increasing the mobile phase composition from 0 to 55% B over 115 min. The HPLC column was coupled to the mass spectrometer by an in-house manufactured electrospray ionization interface. The heated capillary inlet temperature and electrospray voltage were 200° C. and 2.2 kV, respectively. Data were acquired for 100 min, beginning 65 min after sample injection (15 min into start of buffer B gradient). Orbitrap spectra (AGC 5×10⁵) were collected from 400-2000 m/z at a resolution of 100,000.

The mass spectra were analyzed using the AMT tag approach. The peak lists for each analysis were matched against a mass tag database containing 30,573 tryptic peptides that were previously identified from LC-MS/MS analyses of human plasma. An estimate of the false-positive rate for peptide identifications in our analysis, which was <6%, was obtained by searching the sequence-reversed database.

Statistics.

There were 76 mass spectrometry runs included in the proteomics data, including at least two analyses for each of the 36 samples. A total of 6460 unique peptides were initially identified. The data-analysis process first removed peptides for which there were insufficient identifications to perform a statistical analysis, which reduced the peptide number to 3814. Next, the peptide abundance measurements were normalized via regression based on all the peptide signals for that mass spectrometer run and then averaged across replicate runs for each sample. The averaged signal intensities were normalized for each sample based on the median absolute deviation of the signal intensity for all peptides identified in each sample. Finally, the data were subjected to two statistical tests to determine peptides having differential abundance due to either signal intensities or presence-absence. A non-parametric Mann-Whitney test was performed using MatLab 2009 to compare signal intensities. Differences in detection incidence was determined using a modified Chi-square test, called a G-test. Using either test, 647 peptides were identified with a p-value of 0.05 or less.

Normalized peptide abundance values were used for protein inference; the peptide abundance measurements were weighted and combined to calculate the relative protein abundances in the two groups using RRollup within DAnTEm. Only proteins represented by two or more unique peptides were analyzed. Peptide redundancy was reduced with Protein Prophet and by manually selecting characterized proteins over predicted or hypothetical proteins.

Ingenuity Pathway Analysis.

Differentially regulated proteins were analyzed for common biological functions using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Mountain View, Calif.) software. To infer significant biological functions, all proteins that were significantly different between groups and their corresponding ratiometric values (HL+/HL−; minimum of 1.5-fold change) were analyzed by IPA. The significance values for biological function were determined using the right-tailed Fisher's Exact Test.

Results and Discussion

To identify potential circulating biomarkers for HL in a susceptible population, we used the AMT tag LC-MS approach to compare the plasma proteomes from 36 HIV-infected patients with or without HL. The HIV-infected patients without HL served as the control group to identify protein changes associated with HL. The relatively high-throughput characteristics of this approach enabled duplicate analyses of each of the 36 plasma samples, thereby improving data quality. The subject characteristics are described in Table 1. The proteomics analysis identified 3814 peptides across all of the samples, which corresponded to 629 proteins. Of these 3814 peptides, 647 were significantly different between the two disease states, which corresponded to 152 proteins (Tables S1 and S2). Sixty of these proteins met our criteria of being both significantly different between the two groups and having at least 1.5-fold difference in the normalized signal (Table S3). This protein list included well-known acute-phase inflammatory proteins, including C-reactive protein and serum amyloid proteins. To better identify common biological functions within these 60 proteins, Ingenuity Pathway Analysis (IPA) was utilized. In general, proteins that were associated with immune responses and cancer were highly represented in the list of significantly altered biological functions. Many of the proteins we identified are known to be secreted by white blood cells, such as those that infiltrate HL tumors, or by the liver, an important component of the reticuloendothelial system (Table S3). Similarly, the use of IPA to identify common biological functions across the 60 proteins identified “inflammatory response” and “cancer” (Table 2), suggesting that these proteins have a biological relationship with HL. Since only 1% to 2% of the mass of an HL tumor is composed of the cancerous lymphocytes, it may be that the proteins we identified did not originate from these relatively rare cells. Rather, these proteins may be the product of a systemic inflammatory response associated with HL or due to noncancerous leukocytes that form ˜99% of the tumor mass.

TABLE 2 Top BioFunctions and associated proteins, as defined by Ingenuity Pathway Analysis. p-value Name range^(a) Associated proteins^(b) Inflam- 3.0 × 10⁻¹⁰- AHSG, AMBP, APOE, ARHGDIB, B2M, matory 1.1 × 10⁻⁰² C4A/C4B, C8A, CD14, CFD, CRP, GSN, LUM, Re- MBL2, MCAM, MASP1, MSN, PPBP, PNP, sponse PTGDS, PVR, SAA1, SEMA7A, TIMP1 Cancer 9.2 × 10⁻⁰⁹- AHSG, AMPB, APOC1, APOE, ARHGDIB, 1.1 × 10⁻⁰² AZGP1, B2M, C4A/C4B, CD14, CFD, COL6A3, CRP, CST3, EFEMP1, GSN, IGFBP2, KRT10, MCAM, MASP1, PNP, PTGDS, SAA1, SELENBP1, TIMP1, YWHAG ^(a)The p-values reflect the range of all the subcategories that the Ingenuity Pathway Analysis included under the header of Inflammatory Response or Cancer. That is, these two BioFunctions have 39 or 35 subcategories, respectively, and each of these subcategories show significant differences, within the range of p-values shown, between the HIV+ (without HL) and HIV+/HL+ groups. ^(b)Abbreviations are defined in Table S3.

At least three of the proteins we identified have been previously reported to be increased in HL subjects compared to healthy controls, including C-reactive protein, beta-2-microglobulin and lactate dehydrogenase. These prior studies examined HL in the general population, and did not focus on HIV-positive subjects. In addition, these studies measured these proteins by immunoassay, providing analytical verification as well. In the current study, the presence of HIV in the study population could be a confounding factor. For example, the HL subjects appeared to have slightly more advanced cases of HIV, on the average, as suggested by a trend (p=0.07, t-test) towards lower CD4-positive cell counts (Table 1), a result which is consistent with slightly more advanced immunosuppression. Even so, since three of the proteins we identified are increased in HL subjects without HIV, it seems clear that the results for these proteins, at least, are not confounded by differential states of HIV infection. Overall, the present study independently validates three plasma biomarkers for HL and identifies an additional 57 novel plasma proteins that appear to be promising candidate biomarkers based on their relationships with cancer and inflammation. These candidate biomarkers remain to be validated in regards to their association with HL.

The present invention has been described in terms of specific embodiments incorporating details to facilitate the understanding of the principles of construction and operation of the invention. As such, references herein to specific embodiments and details thereof are not intended to limit the scope of the claims appended hereto. It will be apparent to those skilled in the art that modifications can be made in the embodiments chosen for illustration without departing from the spirit and scope of the invention.

TABLE S1 Identified significant peptides Ave HL Ave HL Ratio HL positive negative positive/ GENE (n = (n = HL SYMBOL Protein Reference Peptide 22) 14) negative — P25 IPI:IPI00386965.1 FVTKAEEK 0.22 0.21 1.04 — CDNA FLJ33508 IPI:IPI00166374.1 YNDYLITIK 0.23 fis, clone BRAMY2005094 A1BG Alpha-1B- IPI:IPI00022895.7 SLPAPWLSMAPVSWITPGLK 0.45 0.59 0.77 glycoprotein A2M Alpha-2- IPI:IPI00478003.1 AFQPFFVELTMPYSVIR 7.72 0.32 24.32 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 ASVSVLGDILGSAMQN 0.36 0.61 0.59 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 ATVLNYLPK 7.93 0.43 18.58 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 AVDQSVLLMKPDAELSASS 4.59 macroglobulin VYNLLPEK A2M Alpha-2- IPI:IPI00478003.1 AYAFALAGNQDKR 0.15 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 DMYSFLEDMGLK 6.62 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 DTVIKPLLVEPEGLEK 9.70 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 GGVEDEVTLSAYITIALLEIP 3.16 macroglobulin LTVTHPVVR A2M Alpha-2- IPI:IPI00478003.1 GHFSISIPVK 6.81 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 GPTQEFK 2.20 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 HYDGSYSTFGER 5.25 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 LLIYAVLPTGDVIGDSAK 9.45 0.31 30.49 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 LLLQQVSLPELPGEYSMK 10.03 0.29 34.54 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 LPPNVVEESAR 6.87 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 QGIPFFGQVR 4.59 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 QTVSWAVTPK 8.37 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 SDIAPVAR 3.78 1.61 2.35 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 SIYKPGQTVK 5.37 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 SVSGKPQYMVLVPSLLHTET 12.16 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 TGTHGLLVK 8.95 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 VIKPLLVEPEGLEK 0.84 0.99 0.85 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 VSVQLEASPAFLAVPVEK 7.90 macroglobulin ACTA1 Actin, alpha IPI:IPI00021428.1 AGFAGDDAPR 13.47 20.00 0.67 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 DLTDYLMK 18.97 28.69 0.66 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 DSYVGDEAQSKR 0.79 0.60 1.32 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 EITALAPSTMK 26.67 40.43 0.66 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 HQGVMVGMGQK 10.17 10.44 0.97 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 SYELPDGQVITIGNER 26.79 39.27 0.68 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 YPIEHGIITNWDDMEKIWHH 0.86 skeletal TFYNELR muscle ACTB Actin, IPI:IPI00021439.1 AGFAGDDAPR 13.47 20.00 0.67 cytoplasmic 1 ACTB Actin, IPI:IPI00021439.1 DLTDYLMK 18.97 28.69 0.66 cytoplasmic 1 ACTB Actin, IPI:IPI00021439.1 DSYVGDEAQSKR 0.79 0.60 1.32 cytoplasmic 1 ACTB Actin, IPI:IPI00021439.1 EITALAPSTMK 26.67 40.43 0.66 cytoplasmic 1 ACTB Actin, IPI:IPI00021439.1 HQGVMVGMGQK 10.17 10.44 0.97 cytoplasmic 1 ACTB Actin, IPI:IPI00021439.1 SYELPDGQVITIGNER 26.79 39.27 0.68 cytoplasmic 1 ACTB Actin, IPI:IPI00021439.1 TTGIVMDSGDGVTHTVPIYE 36.07 48.57 0.74 cytoplasmic 1 GYALPHAILR ACTN1 Alpha- IPI:IPI00013508.5 LAILGIHNEVSK 1.17 0.70 1.68 actinin-1 ACTN1 Alpha- IPI:IPI00013508.5 VGWEQLLTTIAR 1.50 1.32 1.13 actinin-1 ADAMTSL2 ADAMTS-like IPI:IPI00644346.2 NFNIAGTVVK 0.68 0.55 1.23 protein 2 AGT Angiotensinogen IPI:IPI00032220.3 STLAFNTYVHFQGK 1.61 AGT Angiotensinogen IPI:IPI00032220.3 VGEVLNSIFFELEADER 0.26 AHSG Alpha-2-HS- IPI:IPI00022431.1 FSVVYAK 80.04 123.13 0.65 glycoprotein ALB Serum albumin IPI:IPI00745872.2 AEFAEVSK 3.86 0.16 23.74 ALB Serum albumin IPI:IPI00745872.2 AVMDDFAAFVEK 26.36 ALB Serum albumin IPI:IPI00745872.2 DVFLGMFLYEYAR 6.14 ALB Serum albumin IPI:IPI00745872.2 FKDLGEENFK 19.32 ALB Serum albumin IPI:IPI00745872.2 FQNALLVR 18.06 0.09 209.25 ALB Serum albumin IPI:IPI00745872.2 KQTALVELVK 6.23 ALB Serum albumin IPI:IPI00745872.2 KYLYEIAR 2.08 2.41 0.86 ALB Serum albumin IPI:IPI00745872.2 LVAASQAALGL 6.02 ALB Serum albumin IPI:IPI00745872.2 LVNEVTEFAK 25.15 ALB Serum albumin IPI:IPI00745872.2 LVTDLTK 5.31 ALB Serum albumin IPI:IPI00745872.2 QNCELFEQLGEYK 1.14 ALB Serum albumin IPI:IPI00745872.2 RHPYFYAPELLFFAK 4.53 ALB Serum albumin IPI:IPI00745872.2 TYETTLEK 5.97 ALB Serum albumin IPI:IPI00745872.2 VFDEFKPLVEEPQNLIK 19.11 ALB Serum albumin IPI:IPI00745872.2 VPQVSTPTLVEVSR 1.26 ALB Serum albumin IPI:IPI00745872.2 YLYEIAR 7.48 ALDH3A1 Aldehyde IPI:IPI00296183.7 FMNSGQTCVAPDYILCDPSI 0.46 dehydrogenase, QNQIVEKLKK dimeric NADP- preferring AMBP AMBP protein IPI:IPI00022426.1 AFIQLWAFDAVK 26.03 45.43 0.57 AMBP AMBP protein IPI:IPI00022426.1 TVAACNLPIVR 2.78 7.69 0.36 Isoform 2 of Ankyrin repeat domain- containing ANKRD6 protein 6 IPI:IPI00218274.1 KRERLK 0.06 ANPEP Aminopeptidase IPI:IPI00221224.6 ALEQALEK 0.21 0.53 0.40 N APOA1 Apolipoprotein IPI:IPI00021841.1 AKPALEDLR 40.63 61.64 0.66 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 FLSALEEYTK 0.67 0.46 1.46 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 LHELQEKLSPLGEEMRDR 0.99 1.38 0.72 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 QKVEPLR 5.27 4.80 1.10 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 QKVEPLRAELQEGAR 4.64 5.86 0.79 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 VEPLRAELQEGAR 4.87 5.23 0.93 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 VQPYLDDFQKK 13.44 32.60 0.41 A-I APOA1 Apolipoprotein IPI:IPI00021841.1 VSFLSALEEYTK 49.59 71.41 0.69 A-I APOA4 Apolipoprotein IPI:IPI00304273.2 DSEKLKEEIGK 0.17 A-IV APOA4 Apolipoprotein IPI:IPI00304273.2 ISASAEELRQR 0.29 0.81 0.35 A-IV APOA4 Apolipoprotein IPI:IPI00304273.2 QLTPYAQR 2.50 2.92 0.86 A-IV APOA4 Apolipoprotein IPI:IPI00304273.2 RRVEPYGENFNK 0.22 A-IV APOA4 Apolipoprotein IPI:IPI00304273.2 VEPYGENFNK 0.48 0.47 1.01 A-IV APOB Apolipoprotein IPI:IPI00022229.1 ALYWVNGQVPDGVSK 0.79 0.47 1.69 B-100 APOB Apolipoprotein IPI:IPI00022229.1 DKIGVELTGR 5.81 B-100 APOB Apolipoprotein IPI:IPI00022229.1 EEEAASGLLTSLKDNVPK 0.38 B-100 APOB Apolipoprotein IPI:IPI00022229.1 ENFAGEATLQR 18.65 17.01 1.10 B-100 APOB Apolipoprotein IPI:IPI00022229.1 ESVKFSSK 0.14 B-100 APOB Apolipoprotein IPI:IPI00022229.1 HIYAISSAALSASYK 1.39 0.64 2.17 B-100 APOB Apolipoprotein IPI:IPI00022229.1 NIQEYLSILTDPDGKGKEK 1.29 6.98 0.19 B-100 APOB Apolipoprotein IPI:IPI00022229.1 QIDDIDVR 8.19 10.09 0.81 B-100 APOB Apolipoprotein IPI:IPI00022229.1 SKEVPEAR 0.18 0.17 1.07 B-100 APOB Apolipoprotein IPI:IPI00022229.1 SKPTVSSSMEFK 0.16 B-100 APOB Apolipoprotein IPI:IPI00022229.1 TEHGSEMLFFGNAIEGK 0.13 0.46 0.27 B-100 APOB Apolipoprotein IPI:IPI00022229.1 TLQGIPQMIGEVIRK 1.09 0.81 1.35 B-100 APOB Apolipoprotein IPI:IPI00022229.1 VLVDHFGYTKDDKHEQDM 0.80 0.31 2.56 B-100 VNGIMLSVEK APOB Apolipoprotein IPI:IPI00022229.1 VRESDEETQIK 0.07 0.19 0.36 B-100 APOB Apolipoprotein IPI:IPI00022229.1 YEVDQQIQVLMDK 0.16 B-100 APOB Apolipoprotein IPI:IPI00022229.1 YKNFATSNK 1.22 1.01 1.20 B-100 APOB Apolipoprotein IPI:IPI00022229.1 YLRTEHGSEMLFFGNAIEGK 0.92 B-100 APOC1 Apolipoprotein IPI:IPI00021855.1 EWFSETFQK 3.00 0.10 30.94 C-I APOC1 Apolipoprotein IPI:IPI00021855.1 LKEFGNTLEDK 7.68 0.30 25.40 C-I APOC1 Apolipoprotein IPI:IPI00021855.1 MREWFSETFQK 3.08 0.38 8.18 C-I APOC1 Apolipoprotein IPI:IPI00021855.1 TPDVSSALDKLKEFGNTLED 1.13 C-I K APOC2 Apolipoprotein IPI:IPI00021856.3 TAAQNLYEK 5.43 2.86 1.90 C-II APOC3 Apolipoprotein IPI:IPI00021857.1 SEAEDASLLSFMQGYMK 1.02 C-III APOE Apolipoprotein E IPI:IPI00021842.1 FWDYLR 3.08 0.96 3.22 APOE Apolipoprotein E IPI:IPI00021842.1 GEVQAMLGQSTEELR 8.71 3.56 2.45 APOE Apolipoprotein E IPI:IPI00021842.1 LEEQAQQIR 0.55 0.12 4.78 APOE Apolipoprotein E IPI:IPI00021842.1 LKSWFEPLVEDMQR 0.77 0.44 1.76 APOE Apolipoprotein E IPI:IPI00021842.1 MEEMGSR 0.29 0.11 2.70 APOE Apolipoprotein E IPI:IPI00021842.1 QWAGLVEK 2.11 0.77 2.74 APOE Apolipoprotein E IPI:IPI00021842.1 RLAVYQAGAR 0.21 APOE Apolipoprotein E IPI:IPI00021842.1 WVQTLSEQVQEELLSSQVT 6.49 2.16 3.01 QELR APOF apolipoprotein F IPI:IPI00299435.3 SGVQQLIQYYQDQK 1.79 APOH Beta-2- IPI:IPI00298828.3 ATVVYQGER 31.67 42.04 0.75 glycoprotein 1 APOH Beta-2- IPI:IPI00298828.3 EHSSLAFWK 27.55 40.14 0.69 glycoprotein 1 APOH Beta-2- IPI:IPI00298828.3 TCPKPDDLPFSTVVPLK 0.34 0.75 0.45 glycoprotein 1 APOL1 42 kDa protein IPI:IPI00852826.2 NWFLKEFPR 1.00 0.38 2.59 APOM Apolipoprotein M IPI:IPI00030739.1 AFLLTPR 2.31 1.34 1.72 APOM Apolipoprotein M IPI:IPI00030739.1 FLLYNR 2.37 1.73 1.37 APOM Apolipoprotein M IPI:IPI00030739.1 KWIYHLTEGSTDLR 0.24 ARHGDIB Rho GDP-dissociation IPI:IPI00003817.3 ETIVLKEGSEYR 4.62 inhibitor 2 ARHGDIB Rho GDP-dissociation IPI:IPI00003817.3 TLLGDGPVVTDPK 0.33 inhibitor 2 ARNTL Isoform MOP3 of Aryl IPI:IPI00217736.1 EMTGSGRR 0.21 hydrocarbon receptor nuclear translocator- like protein 1 ASL Argininosuccinate  IPI:IPI00220267.7 ALLQAQQA 0.39 0.61 0.64 lyase AZGP1 alpha-2- IPI:IPI00166729.4 AGEVQEPELR 11.94 16.22 0.74 glycoprotein 1, zinc AZGP1 alpha-2- IPI:IPI00166729.4 HVEDVPAFQALGSLNDLQF 19.92 31.15 0.64 glycoprotein 1, zinc FR AZGP1 alpha-2- IPI:IPI00166729.4 IDVHWTR 15.39 23.89 0.64 glycoprotein 1, zinc AZGP1 alpha-2- IPI:IPI00166729.4 YSLTYIYTGLSK 22.15 34.77 0.64 glycoprotein 1, zinc B2M Beta-2-microglobulin IPI:IPI00868938.1 IEKVEHSDLSFSK 2.38 B2M Beta-2-microglobulin IPI:IPI00868938.1 IQVYSR 0.75 3.60 0.21 BCHE Cholinesterase IPI:IPI00025864.5 DNNSIITR 7.68 9.51 0.81 BCHE Cholinesterase IPI:IPI00025864.5 WNNYMMDWK 0.35 BHMT Betaine--homocysteine  IPI:IPI00004101.4 AGPWTPEAAVEHPEAVR 1.72 S-methyltransferase 1 BLVRB Flavin reductase IPI:IPI00783862.2 HDLGHFMLR 0.28 BRUNOL4 LYST-interacting  IPI:IPI00386504.1 MAALNMIWAGSRTYDPNLR 0.51 protein LIP9 (Fragment) BRWD1 Isoform B of IPI:IPI00250716.1 ASAVAR 19.37 Bromodomain and WD repeat-containing  protein 1 BTD biotinidase IPI:IPI00218413.2 QEALELMNQNLDIYEQQVM 0.33 0.56 0.59 TAAQK C1QA Complement C1q IPI:IPI00022392.1 SLGFCDTTNK 1.32 1.28 1.03 subcomponent subunit A C1QB complement component 1, IPI:IPI00477992.1 DQTIRFDHVITNMNNNYEPR 0.66 q subcomponent, B chain C1R Complement C1r IPI:IPI00296165.5  YTTEIIK 4.66 6.69 0.70 subcomponent C1R; Complement C1r IPI:IPI00296165.5 EFMSQGNK 0.59 0.85 0.69 C17orf1 subcomponent C1RL Complement C1r-like IPI:IPI00009793.3 GSEAINAPGDNPAK 0.42 0.43 0.98 protein C1RL Complement C1r-like IPI:IPI00009793.3 LGNFPWQAFTSIHGR 0.13 protein C1S Complement C1s IPI:IPI00017696.1 EVKVEKPTADAEAYVFTPN 6.25 9.93 0.63 subcomponent MICAGGEKG C1S Complement C1s IPI:IPI00017696.1 IIGGSDADIK 2.17 subcomponent C1S Complement C1s IPI:IPI00017696.1 TNFDNDIALVR 5.26 6.98 0.75 subcomponent C1S Complement C1s IPI:IPI00017696.1 VKNYVDWIMK 0.50 1.73 0.29 subcomponent C2 Complement C2 IPI:IPI00303963.1 SSGQWQTPGATR 0.45 0.63 0.71 (Fragment) C2 Complement C2 IPI:IPI00303963.1 TPWHVTIKPK 0.31 (Fragment) C3 Complement C3 IPI:IPI00783987.2 APSTWLTAYVVK 45.19 52.79 0.86 (Fragment) C3 Complement C3 IPI:IPI00783987.2 DQLTCNKFDLK 0.28 0.49 0.58 (Fragment) C3 Complement C3 IPI:IPI00783987.2 DSCVGSLVVK 5.38 7.71 0.70 (Fragment) C3 Complement C3 IPI:IPI00783987.2 EALKLEEK 39.64 49.25 0.80 (Fragment) C3 Complement C3 IPI:IPI00783987.2 ETKENEGFTVTAEGK 0.12 0.08 1.55 (Fragment) C3 Complement C3 IPI:IPI00783987.2 EYVLPSFEVIVEPTEKFYYIY 7.25 (Fragment) NEK C3 Complement C3 IPI:IPI00783987.2 GQGTLSVVTMYHAK 71.12 89.56 0.79 (Fragment) C3 Complement C3 IPI:IPI00783987.2 IEGDHGAR 0.31 0.69 0.45 (Fragment) C3 Complement C3 IPI:IPI00783987.2 ILLQGTPVAQMTEDAVDAE 6.56 31.38 0.21 (Fragment) RLK C3 Complement C3 IPI:IPI00783987.2 PESWLWNVEDLKEPPK 0.14 (Fragment) C3 Complement C3 IPI:IPI00783987.2 PPADLSDQVPDTESETR 0.18 (Fragment) C3 Complement C3 IPI:IPI00783987.2 PYVIVPLKTGLQEVEVK 0.68 1.71 0.40 (Fragment) C3 Complement C3 IPI:IPI00783987.2 SGSDEVQVGQQR 39.75 46.61 0.85 (Fragment) C3 Complement C3 IPI:IPI00783987.2 SINTHPSQKPLSITVR 0.20 (Fragment) C3 Complement C3 IPI:IPI00783987.2 VLLDGVQNPR 83.31 104.55 0.80 (Fragment) C3 Complement C3 IPI:IPI00783987.2 VVLVSLQSGYLFIQTDK 4.92 5.73 0.86 (Fragment) C4A Complement component IPI:IPI00643525.1 GQIVFMNREPK 11.87 5.23 2.27 4A C4A Complement component IPI:IPI00643525.1 GSGATFSHYYYMILSR 0.52 4A C4A Complement component IPI:IPI00643525.1 HLVPGAPFLLQALVR 15.53 5.25 2.95 4A C4A Complement component IPI:IPI00643525.1 LGQYASPTAKR 0.17 0.26 0.64 4A C4A Complement component IPI:IPI00643525.1 LNMGITDLQGLR 72.56 46.19 1.57 4A C4A Complement component IPI:IPI00643525.1 LVNGQSHISLSK 0.48 0.55 0.87 4A C4A Complement component IPI:IPI00643525.1 PNMIPDGDFNSYVR 0.43 4A C4A Complement component IPI:IPI00643525.1 SMQGGLVGNDETVALTAFV 0.40 0.13 3.05 4A TIALHHGLAVFQDEGAEPLK QR C4A Complement component IPI:IPI00643525.1 SPSVVHLGVPLSVGVQLQD 0.45 0.70 0.64 4A VPR C4A Complement component IPI:IPI00643525.1 TITVMVENSHGLR 0.29 4A C4B C4B1 IPI:IPI00418163.3 GQIVFMNREPK 11.87 5.23 2.27 C4B C4B1 IPI:IPI00418163.3 GSGATFSHYYYMILSR 0.52 C4B C4B1 IPI:IPI00418163.3 HLVPGAPFLLQALVR 15.53 5.25 2.95 C4B C4B1 IPI:IPI00418163.3 LGQYASPTAKR 0.17 0.26 0.64 C4B C4B1 IPI:IPI00418163.3 LNMGITDLQGLR 72.56 46.19 1.57 C4B C4B1 IPI:IPI00418163.3 LQETSNWLLSQQQADGSFQ 30.40 17.38 1.75 DLSPVIHR C4B C4B1 IPI:IPI00418163.3 LVNGQSHISLSK 0.48 0.55 0.87 C4B C4B1 IPI:IPI00418163.3 PNMIPDGDFNSYVR 0.43 C4B C4B1 IPI:IPI00418163.3 PVAFSVVPTAATAVSLK 1.05 7.66 0.14 C4B C4B1 IPI:IPI00418163.3 SMQGGLVGNDETVALTAFV 0.40 0.13 3.05 TIALHHGLAVFQDEGAEPLK QR C4B C4B1 IPI:IPI00418163.3 SPSVVHLGVPLSVGVQLQD 0.45 0.70 0.64 VPR C4B C4B1 IPI:IPI00418163.3 TITVMVENSHGLR 0.29 C4BPA C4b-binding protein  IPI:IPI00021727.1 GVGWSHPLPQCEIVK 0.29 alpha chain C5 Complement C5 IPI:IPI00032291.2 ATLLDIYK 5.86 7.64 0.77 C5 Complement C5 IPI:IPI00032291.2 DSLDQLVGGVPVTLNAQTI 3.49 4.51 0.77 DVNQETSDLDPSK C5 Complement C5 IPI:IPI00032291.2 EALQIK 0.40 0.45 0.89 C5 Complement C5 IPI:IPI00032291.2 ETVLTFIDPEGSEVDMVEEI 8.40 10.50 0.80 DHIGIISFPDFK C5 Complement C5 IPI:IPI00032291.2 IDTQDIEASHYR 4.23 6.45 0.66 C5 Complement C5 IPI:IPI00032291.2 KIEEIAAK 3.68 5.19 0.71 C5 Complement C5 IPI:IPI00032291.2 LKEGMLSIMSYR 2.26 3.67 0.62 C5 Complement C5 IPI:IPI00032291.2 LQGTLPVEAR 14.02 18.08 0.78 C5 Complement C5 IPI:IPI00032291.2 MVETTAYALLTSLNLKDINY 0.47 4.22 0.11 VNPVIK C5 Complement C5 IPI:IPI00032291.2 NFEITIK 4.50 6.52 0.69 C5 Complement C5 IPI:IPI00032291.2 QLPGGQNPVSYVYLEVVSK 1.15 1.61 0.72 C5 Complement C5 IPI:IPI00032291.2 QYLIMGK 2.80 3.67 0.76 C5 Complement C5 IPI:IPI00032291.2 TDAPDLPEENQAR 2.67 4.11 0.65 C5 Complement C5 IPI:IPI00032291.2 TLLPVSKPEIR 17.92 23.93 0.75 C5 Complement C5 IPI:IPI00032291.2 VFQFLEK 10.48 15.04 0.70 C5 Complement C5 IPI:IPI00032291.2 VQVKDSLDQLVGGVPVTLN 1.18 AQTIDVNQETSDLDPSK C5 Complement C5 IPI:IPI00032291.2 VVPEGVKR 2.62 3.94 0.67 C5 Complement C5 IPI:IPI00032291.2 WLSEEQR 3.06 4.30 0.71 C5 Complement C5 IPI:IPI00032291.2 YGMWTIK 3.29 4.61 0.71 C5 Complement C5 IPI:IPI00032291.2 YNFSFR 3.90 5.57 0.70 C6 Complement component 6 IPI:IPI00009920.2 IGESIELTCPK 7.46 6.33 1.18 C6 Complement component 6 IPI:IPI00009920.2 LSEKHEGSFIQGAEK 0.56 0.81 0.70 C7 Complement component IPI:IPI00296608.6 AASGTQNNVLRGEPFIR 0.18 C7 C7 Complement component IPI:IPI00296608.6 GGGAGFISGLSYLELDNPAG 1.10 1.41 0.78 C7 NK C7 Complement component IPI:IPI00296608.6 VLFYVDSEKLK 0.49 0.90 0.55 C7 C8A Complement component IPI:IPI00011252.1 SLLQPNK 6.84 9.99 0.68 C8 alpha chain C8A Complement component IPI:IPI00011252.1 YNPVVIDFEMQPIHEVLR 1.61 1.47 1.09 C8 alpha chain C8B Complement component IPI:IPI00294395.1 GGASEHITTLAYQELPTADL 2.13 1.76 1.21 C8 beta chain MQEWGDAVQYNPAIIK C9 Complement component IPI:IPI00022395.1 KGVELK 0.12 C9 C9 Complement component IPI:IPI00022395.1 TEHYEEQIEAFK 11.87 9.19 1.29 C9 CA1 Carbonic anhydrase 1 IPI:IPI00215983.3 GGPFSDSYR 0.94 CA1 Carbonic anhydrase 1 IPI:IPI00215983.3 HDTSLKPISVSYNPATAK 2.31 CAl Carbonic anhydrase 1 IPI:IPI00215983.3 SLLSNVEGDNAVPMQHNNR 2.88 PTQPLK CACNA2D1 Dihydropyridine receptor IPI:IPI00470535.1 TPNKIDLYDVR 1.41 0.51 2.74 alpha 2 subunit CCDC89 Coiled-coil domain- IPI:IPI00167663.1 ERELNGK 10.66 14.27 0.75 containing protein 89 CD14 Monocyte differentiation IPI:IPI00029260.2 AFPALTSLDLSDNPGLGER 0.53 0.46 1.14 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2 ATVNPSAPR 0.36 0.21 1.73 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2 FPAIQNLALR 0.37 0.34 1.11 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2 ITGTMPPLPLEATGLALSSLR 0.65 0.29 2.29 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2 LTVGAAQVPAQLLVGALR 0.38 0.31 1.25 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2 SWLAELQQWLKPGLK 0.33 antigen CD14 CDH5 Cadherin-5 IPI:IPI00012792.1 VHDVNDNWPVFTHR 0.52 CDKL1 cyclin-dependent kinase- IPI:IPI00023527.5 SDVDQLYLIR 0.37 like 1 CECR1 Cat eye syndrome  IPI:IPI00303071.4 WILLEDYRK 0.35 critical region  protein 1 CEP110 Centrosomal protein IPI:IPI00376383.2 AELEKER 0.06 0.12 0.52 110 kDa CES1 Isoform 1 of Liver IPI:IPI00010180.4 QEFGWLIPMQLMSYPLSEG 0.66 carboxylesterase 1 QLDQK CFB Isoform 1 of Complement IPI:IPI00019591.1 LEDSVTYHCSR 0.38 0.38 0.98 factor B (Fragment) CFB Isoform 1 of Complement IPI:IPI00019591.1 LQDEDLGFL 17.49 20.39 0.86 factor B (Fragment) CFB Isoform 1 of Complement IPI:IPI00019591.1 QLNEINYEDHKLK 0.35 2.99 0.12 factor B (Fragment) CFD Complement factor D IPI:IPI00165972.3 LYDVLR 0.48 preproprotein CFH Isoform 1 of Complement IPI:IPI00029739.5 IDVHLVPDR 33.22 40.39 0.82 factor H CFI Complement factor I IPI:IPI00291867.3 IVIEYVDR 7.42 9.34 0.79 CFI Complement factor I IPI:IPI00291867.3 TMFICK 0.50 CFI Complement factor I IPI:IPI00291867.3 VANYFDWISYHVGR 0.21 0.36 0.57 CFL1 Cofilin-1 IPI:IPI00012011.6 EILVGDVGQTVDDPYATFV 0.21 K CHIT1 Isoform 3 of IPI:IPI00375364.1 FTTLVQDLANAFQQEAQTS 3.66 1.77 2.07 Chitotriosidase-1 GK CLEC3B Tetranectin IPI:IPI00009028.1 KDVVNTK 0.03 0.08 0.42 CLEC3B Tetranectin IPI:IPI00009028.1 LDTLAQEVALLK 3.37 5.17 0.65 CLEC3B Tetranectin IPI:IPI00009028.1 MFEELK 0.19 0.23 0.85 CLEC3B Tetranectin IPI:IPI00009028.1 SRLDTLAQEVALLK 0.66 1.07 0.61 CNDP1 Beta-Ala-His dipeptidase IPI:IPI00064667.4 DGSTIPIAK 0.41 0.27 1.52 CNDP1 Beta-Ala-His dipeptidase IPI:IPI00064667.4 HLEDVFSKR 0.16 CNDP1 Beta-Ala-His dipeptidase IPI:IPI00064667.4 MFQEIVHK 0.20 CNTN1 Isoform 1 of  IPI:IPI00029751.1 YVHKDETMSPSTAFQVK 0.30 Contactin-1 COL1A2 Collagen alpha-2(I)  IPI:IPI00304962.3 DYEVDATLK 0.19 0.30 0.63 chain COL6A3 alpha 3 type VI  IPI:IPI00022200.2 SDDEVDDPAVELK 0.17 46.32 0.00 collagen isoform 1 CP Ceruloplasmin IPI:IPI00017601.1 EVGPTNADPVCLAK 8.29 11.01 0.75 CP Ceruloplasmin IPI:IPI00017601.1 KLISVDTEHSNIYLQNGPDR 9.19 8.60 1.07 CP Ceruloplasmin IPI:IPI00017601.1 PDQVDKEDEDFQESNK 0.26 0.44 0.59 CP Ceruloplasmin IPI:IPI00017601.1 PVWLGFLGPIIK 0.31 0.37 0.85 CPB2 Isoform 1 of IPI:IPI00329775.7 YSFTIELR 0.63 0.34 1.83 Carboxypeptidase B2 CPN1 Carboxypeptidase N IPI:IPI00010295.1 IVQLIQDTR 2.44 3.28 0.74 catalytic chain CPN1 Carboxypeptidase N IPI:IPI00010295.1 TASTPTPDDKLFQK 0.38 0.42 0.90 catalytic chain CPN2 similar to IPI:IPI00738433.1 AGGSWDLAVQER 0.99 1.29 0.77 Carboxypeptidase N subunit 2 CPN2 similar to IPI:IPI00738433.1 LSNNALSGLPQGVFGK 2.44 3.86 0.63 Carboxypeptidase N subunit 2 CR2 Isoform B of Complement IPI:IPI00216985.1 CVIAGQGVAWTK 0.80 receptor type 2 CRP C-reactive protein IPI:IPI00022389.1 AFVFPK 7.08 4.75 1.49 CRP C-reactive protein IPI:IPI00022389.1 APLTKPLK 15.53 5.33 2.92 CRP C-reactive protein IPI:IPI00022389.1 ESDTSYVSLK 27.67 7.66 3.61 CRP C-reactive protein IPI:IPI00022389.1 GYSIFSYATK 23.94 12.45 1.92 CRP C-reactive protein IPI:IPI00022389.1 KAFVFPK 24.11 5.76 4.19 CRP C-reactive protein IPI:IPI00022389.1 QDNEILIFWSK 3.60 3.94 0.91 CRP C-reactive protein IPI:IPI00022389.1 RQDNEILIFWSK 24.62 17.36 1.42 CRP C-reactive protein IPI:IPI00022389.1 YEVQGEVFTKPQLWP 19.78 11.80 1.68 CRYZ Quinone oxidoreductase IPI:IPI00000792.1 VFEFGGPEVLK 0.56 CST3 Cystatin-C IPI:IPI00032293.1 ASNDMYHSR 0.25 CST3 Cystatin-C IPI:IPI00032293.1 LVGGPMDASVEEEGVRR 1.32 CTSA cathepsin A IPI:IPI00640525.2 YGDSGEQIAGFVK 0.33 CTSB Cathepsin B IPI:IPI00295741.4 SGVYQHVTGEMMGGHAIR 1.34 2.07 0.65 CUL4A Isoform 1 of Cullin-4A IPI:IPI00419273.5 RIESLIDR 4.35 6.76 0.64 DKK3 Dickkopf-related  IPI:IPI00002714.1 LLDLITWELEPDGALDR 13.43 protein 3 DSTN Destrin IPI:IPI00473014.5 MIYASSK 0.54 0.25 2.21 ECM1 Extracellular matrix IPI:IPI00645849.1 NLPATDPLQR 0.51 0.77 0.67 protein 1 EFEMP1 Isoform 1 of EGF- IPI:IPI00029658.1 QTSPVSAMLVLVK 0.15 0.46 0.34 containing fibulin-like extracellular matrix  protein 1 ERAP1 Isoform 2 of  IPI:IPI00165949.2 DMNEVETQFK 0.18 Endoplasmic reticulum  aminopeptidase 1 ERC1 Isoform 2 of ELKS/RAB6- IPI:IPI00171230.6 QTLNARDESIKK 0.28 interacting/CAST family member 1 F10 Coagulation factor X IPI:IPI00019576.1 APACLPERDWAESTLMTQK 0.62 F10 Coagulation factor X IPI:IPI00019576.1 MLEVPYVDR 0.57 1.48 0.39 F11 Isoform 1 of  IPI:IPI00008556.1 ERPGVYTNVVEYVDWILEK 0.14 Coagulation factor XI F11 Isoform 1 of  IPI:IPI00008556.1 MAESGYDIALLK 0.21 0.45 0.48 Coagulation factor XI F2 Prothrombin (Fragment) IPI:IPI00019568.1 GQPSVLQVVNLPIVERPVCK 0.42 0.68 0.62 F2 Prothrombin (Fragment) IPI:IPI00019568.1 IVEGSDAEIGMSPWQVMLF 12.26 18.80 0.65 R F2 Prothrombin (Fragment) IPI:IPI00019568.1 SGIECQLWR 0.24 0.57 0.42 F2 Prothrombin (Fragment) IPI:IPI00019568.1 SLEDKTERELLESYIDGR 3.18 F2 Prothrombin (Fragment) IPI:IPI00019568.1 TATSEYQTFFNPR 25.22 36.62 0.69 F2 Prothrombin (Fragment) IPI:IPI00019568.1 VIDQFGE 19.63 27.80 0.71 F5 Coagulation factor V IPI:IPI00022937.4 ASEFLGYWEPR 0.10 FAM71A Protein FAM71A IPI:IPI00217863.2 YAPIFESDFIQITK 0.39 0.35 1.12 FBXO32 F-box only protein 32  IPI:IPI00056487.1 LDFSTAILDSR 0.16 FCGBP IgGFc-binding protein IPI:IPI00242956.4 LLFDGDAHLLMSIPSPFR 0.21 FCGR3A Low affinity IPI:IPI00218834.9 AVVFLEPQWYR 0.41 immunoglobulin gamma Fc region receptor III-A FCN3 Isoform 1 of Ficolin-3 IPI:IPI00293925.2 FSEGTAGDSLSLHSGR 0.13 FGA Isoform 1 of Fibrinogen IPI:IPI00021885.1 MELERPGGNEITR 14.64 0.77 19.07 alpha chain FGA Isoform 1 of Fibrinogen IPI:IPI00021885.1 MELERPGGNEITR 0.46 0.14 3.35 alpha chain FGA Isoform 1 of Fibrinogen IPI:IPI00021885.1 NPSSAGSWNSGSSGPGSTG 2.82 alpha chain NR FGA Isoform 1 of Fibrinogen IPI:IPI00021885.1 SRIEVLKR 0.30 alpha chain FGB Fibrinogen beta chain IPI:IPI00298497.3 MGPTELLIEMEDWKGDK 0.40 FGG Gamma-B of Fibrinogen IPI:IPI00021891.5 HLISTQSAIPYALR 0.19 gamma chain FGG Gamma-B of Fibrinogen IPI:IPI00021891.5 HLSPTGTTEFWLGNEK 0.22 gamma chain FGG Gamma-B of Fibrinogen IPI:IPI00021891.5 KMLEEIMK 0.37 gamma chain FGG Gamma-B of Fibrinogen IPI:IPI00021891.5 MIDAATLK 1.23 gamma chain FGG Gamma-B of Fibrinogen IPI:IPI00021891.5 MIDAATLK 2.25 0.76 2.97 gamma chain FLJ22662 hypothetical protein IPI:IPI00016255.4 KDPYSR 0.33 LOC79887 FLJ45139 CDNA FLJ45139 fis,  IPI:IPI00418931.1 TVSIPR 62.56 77.85 0.80 clone BRAWH3039623 FLNA filamin A, alpha  IPI:IPI00302592.2 AFGPGLQGGSAGSPAR 1.81 1.08 1.67 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 AYGPGIEPTGNMVK 3.41 0.56 6.13 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 GKLDVQFSGLTK 0.80 0.40 1.98 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 IANLQTDLSDGLR 2.05 1.14 1.80 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 IQQNTFTR 0.72 0.56 1.30 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 LIALLEVLSQK 1.88 1.57 1.20 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 LPQLPITNFSR 2.00 1.55 1.29 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 TGVAVNKPAEFTVDAK 1.17 0.45 2.57 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 VDVGKDQEFTVK 0.83 0.46 1.80 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 VTAQGPGLEPSGNIANK 2.24 1.02 2.20 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 VTVLFAGQHIAK 0.95 0.65 1.46 isoform 1 FLNB Isoform 1 of Filamin-B IPI:IPI00289334.1 IQQNTFTR 0.72 0.56 1.30 FLNB Isoform 1 of Filamin-B IPI:IPI00289334.1 LIALLEVLSQK 1.88 1.57 1.20 FN1 Isoform 1 of  IPI:IPI00022418.1 GATYNIIVEALK 0.41 Fibronectin FN1 Isoform 1 of  IPI:IPI00022418.1 ITGYIIK 0.58 Fibronectin FN1 Isoform 1 of  IPI:IPI00022418.1 SYTITGLQPGTDYK 0.38 Fibronectin FN1 Isoform 1 of  IPI:IPI00022418.1 VGDTYERPK 0.13 Fibronectin FN1 Isoform 1 of  IPI:IPI00022418.1 VTWAPPPSIDLTNFLVR 0.49 Fibronectin FN1 Isoform 1 of  IPI:IPI00022418.1 YEKPGSPPR 0.21 0.04 5.18 Fibronectin FTL Ferritin light chain IPI:IPI00738499.2 LGGPEAGLGEYLFER 2.66 GAPDH Glyceraldehyde-3- IPI:IPI00219018.7 GALQNIIPASTGAAK 2.28 1.61 1.42 phosphate dehydrogenase GAPDH Glyceraldehyde-3- IPI:IPI00219018.7 VDIVAINDPFIDLNYMVYMF 0.81 1.39 0.58 phosphate dehydrogenase QYDSTHGK GAPDH Glyceraldehyde-3- IPI:IPI00219018.7 VVDLMAHMASKE 1.18 0.57 2.08 phosphate dehydrogenase GC Vitamin D-binding  IPI:IPI00555812.4 DKYTFELSR 0.63 0.17 3.70 protein GC Vitamin D-binding  IPI:IPI00555812.4 ELSSFIDK 15.57 10.11 1.54 protein GC Vitamin D-binding  IPI:IPI00555812.4 SINSPPLYCDSEIDAELKNIL 0.13 protein GGH Gamma-glutamyl IPI:IPI00023728.1 MFQNFPTELLLSLAVEPLTA 0.18 hydrolase NFHK GGH Gamma-glutamyl IPI:IPI00023728.1 TAFYLAEFFVNEAR 0.20 hydrolase GLRX Glutaredoxin-1 IPI:IPI00219025.3 LKQIGALQ 85.27 121.89 0.70 GOLGA4 Isoform 1 of Golgin IPI:IPI00013272.1 EFNTQLAQKE 0.20 subfamily A member 4 GP1BA platelet glycoprotein  IPI:IPI00748955.2 LTSLPLGALR 0.87 0.91 0.95 Ib alpha polypeptide GP1BA platelet glycoprotein  IPI:IPI00748955.2 TLPPGLLTPTPK 0.46 0.30 1.56 Ib alpha polypeptide GPLD1 Isoform 1 of IPI:IPI00299503.2 FGGVLHLSDLDDDGLDEIIM 0.22 0.56 0.40 Phosphatidylinositol- AAPLR glycan-specific phospholipase D GPLD1 Isoform 1 of IPI:IPI00299503.2 ILEGFQPSGR 0.32 0.57 0.56 Phosphatidylinositol- glycan-specific phospholipase D GPT Alanine amino- IPI:IPI00217458.3 LLVAGEGHTR 0.11 transferase 1 GRM5 glutamate receptor, IPI:IPI00789949.1 KRDQTLMLSFMR 0.96 1.62 0.59 metabotropic 5 GSG1L GSG1-like isoform 1 IPI:IPI00152159.3 SFIDLAPASEK 0.73 0.58 1.26 GSN Gelsolin IPI:IPI00026314.1 AGALNSNDAFVLK 12.54 24.33 0.52 GSN Gelsolin IPI:IPI00026314.1 AGKEPGLQIWR 5.68 12.22 0.47 GSN Gelsolin IPI:IPI00026314.1 AQPVQVAEGSEPDGFWEAL 2.43 5.88 0.41 GGK GSN Gelsolin IPI:IPI00026314.1 AVEVLPK 1.49 2.94 0.51 GSN Gelsolin IPI:IPI00026314.1 DSQEEEKTEALTSAK 0.76 1.43 0.54 GSN Gelsolin IPI:IPI00026314.1 EGGQTAPASTR 0.23 0.36 0.64 GSN Gelsolin IPI:IPI00026314.1 EVQGFESATFLGYFK 5.76 11.95 0.48 GSN Gelsolin IPI:IPI00026314.1 GASQAGAPQGR 1.32 2.71 0.49 GSN Gelsolin IPI:IPI00026314.1 GGVASGFK 0.31 0.61 0.51 GSN Gelsolin IPI:IPI00026314.1 HVVPNEVVVQR 9.30 19.43 0.48 GSN Gelsolin IPI:IPI00026314.1 IEGSNKVPVDPATYGQFYG 2.55 4.09 0.63 GDSYIILYNYR GSN Gelsolin IPI:IPI00026314.1 MDAHPPR 1.71 3.33 0.51 GSN Gelsolin IPI:IPI00026314.1 PALPAGTEDTAKEDAANR 0.16 0.28 0.57 GSN Gelsolin IPI:IPI00026314.1 QTQVSVLPEGGETPLFK 9.00 19.74 0.46 GSN Gelsolin IPI:IPI00026314.1 RYIETDPANR 0.21 0.37 0.56 GSN Gelsolin IPI:IPI00026314.1 TASDFITK 6.07 12.18 0.50 GSN Gelsolin IPI:IPI00026314.1 TGAQELLR 8.51 17.56 0.48 GSN Gelsolin IPI:IPI00026314.1 TPITVVK 0.66 1.32 0.50 GSN Gelsolin IPI:IPI00026314.1 TPSAAYLWVGTGASEAEK 2.75 5.59 0.49 GSN Gelsolin IPI:IPI00026314.1 TPSAAYLWVGTGASEAEKT 1.04 3.40 0.31 GAQELLR GSN Gelsolin IPI:IPI00026314.1 VPEARPNSMVVEHPEFLK 5.34 12.46 0.43 GSN Gelsolin IPI:IPI00026314.1 VPFDAATLHTSTAMAAQHG 7.35 15.87 0.46 MDDDGTGQK GSN Gelsolin IPI:IPI00026314.1 YIETDPANR 1.99 4.32 0.46 GULP1 Isoform 1 of PTB  IPI:IPI00790010.1 IQDLETENMELK 1.14 domain-containing engulfment adapter protein 1 HBA2;  Hemoglobin subunit  IPI:IPI00410714.5 MFLSFPTTK 10.38 26.76 0.39 HBA1 alpha HELLS Isoform 1 of Lymphoid- IPI:IPI00010590.2 NKDSNSIIK 0.17 specific helicase HGFAC Hepatocyte growth  IPI:IPI00029193.1 EALVPLVADHK 0.41 0.52 0.77 factor activator HOM-TES-1 hypothetical protein IPI:IPI00022868.3 MKVDMDICR 0.44 0.43 1.04 LOC25900 isoform 4 HP Haptoglobin IPI:IPI00641737.1 HYEGSTVPEK 3.73 1.42 2.62 HP Haptoglobin IPI:IPI00641737.1 LRTEGDGVYTLNDK 10.04 0.37 27.05 HP Haptoglobin IPI:IPI00641737.1 PECEAVCGKPK 0.09 HPR Isoform 1 of  IPI:IPI00477597.1 LRTEGDGVYTLNDK 10.04 0.37 27.05 Haptoglobin- related protein HPR Isoform 1 of  IPI:IPI00477597.1 PECEAVCGKPK 0.09 Haptoglobin- related protein HPX Hemopexin IPI:IPI00022488.1 EVGTPHGIILDSVDAAFICPG 0.90 1.92 0.47 SSR HPX Hemopexin IPI:IPI00022488.1 VDGALCMEK 3.41 3.81 0.90 HPX Hemopexin IPI:IPI00022488.1 YYCFQGNQFLR 3.47 5.76 0.60 HRG Histidine-rich  IPI:IPI00022371.1 DVEALDLESPK 0.24 glycoprotein HSPA8 Heat shock 70 kDa IPI:IPI00795040.1 DAGTIAGLNVLR 0.33 protein 8 isoform  2 variant (Fragment) HSPA8 Heat shock 70 kDa  IPI:IPI00795040.1 NQVAMNPTNTVFDAKR 0.30 protein 8 isoform  2 variant (Fragment) ICAM1 Intercellular adhesion IPI:IPI00008494.4 LLGIETPLPK 0.80 molecule 1 ICAM1 Intercellular adhesion IPI:IPI00008494.4 VELAPLPSWQPVGK 0.57 molecule 1 IGF1 Insulin-like growth  IPI:IPI00001610.1 RLEMYCAPLKPAK 0.37 factor IA IGFALS Insulin-like growth  IPI:IPI00020996.3 LAYLQPALFSGLAELR 3.49 3.14 1.11 factor-binding  protein complex acid labile chain IGFALS Insulin-like growth  IPI:IPI00020996.3 NLIAAVAPGAFLGLK 2.08 2.02 1.03 factor-binding  protein complex acid labile chain IGFBP2 Insulin-like growth  IPI:IPI00297284.1 GGKHHLGLEEPK 0.17 factor-binding  protein 2 IGFBP6 Insulin-like growth  IPI:IPI00029235.1 HLDSVLQQLQTEVYR 0.28 factor-binding  protein 6 IGHM IGHM protein IPI:IPI00477090.6 LICQATGFSPR 0.25 IGL@ IGL@ protein IPI:IPI00154742.6 ATLVCLISDFYPGAVTVAW 1.60 0.45 3.58 K IGLV7-43 Ig lambda chain V  IPI:IPI00022890.1 FSGSLLGGK 0.38 region 4A ITGA2B integrin alpha 2b IPI:IPI00218629.2 NVGSQTLQTFK 0.25 preproprotein ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 DTAVDGVFIR 0.13 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 ELAAQTIKK 8.21 14.31 0.57 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 EVAFDLEIPK 28.72 46.70 0.62 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 FAHYVVTSQVVNTANEAR 10.92 17.76 0.61 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 GHMLENHVER 6.40 11.30 0.57 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 GIEILNQVQESLPELSNHASI 3.42 4.93 0.69 inhibitor heavy  LIMLTDGDPTEGVTDR chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 GMADQDGLKPTIDKPSEDSP 27.16 43.87 0.62 inhibitor heavy  PLEMLGPR chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 GSLVQASEANLQAAQDFVR 15.68 24.71 0.63 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 IADNKQSSFK 0.86 1.16 0.74 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 ILGDMQPGDYFDLVLFGTR 22.32 47.17 0.47 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 KAAISGENAGLVR 7.53 12.44 0.61 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 MSLDYGFVTPLTSMSIR 10.01 17.68 0.57 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 MSLDYGFVTPLTSMSIR 0.28 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 NHMQYEIVIK 11.50 17.77 0.65 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 QAVDTAVDGVFIR 10.25 16.99 0.60 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 QYYEGSEIVVAGR 2.23 1.21 1.84 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 RQAVDTAVDGVFIR 0.50 0.58 0.86 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 VTFQLTYEEVLKR 5.67 7.77 0.73 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 VTYDVSR 6.57 10.00 0.66 inhibitor heavy  chain H1 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 AIFILNEANNLGLLDPNSVSL 4.89 8.31 0.59 inhibitor heavy  IILVSDGDPTVGELK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 DKHADPDFTR 3.35 5.99 0.56 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 ENIQDNISLFSLGMGFDVDY 2.43 4.88 0.50 inhibitor heavy  DFLKR chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 FDPAKLDQIESVITATSANT 6.94 12.15 0.57 inhibitor heavy  QLVLETLAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 FDPAKLDQIESVITATSANT 6.94 12.15 0.57 inhibitor heavy  QLVLETLAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 FDPAKLDQIESVITATSANT 0.09 inhibitor heavy  QLVLETLAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 FLHVPDTFEGHFDGVPVISK 42.05 67.72 0.62 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 FYNQVSTPLLR 31.04 54.21 0.57 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 HADPDFTR 8.05 12.82 0.63 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 IQPSGGTNINEALLR 45.53 79.08 0.58 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 IYGNQDTSSQLK 3.74 4.70 0.80 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 IYGNQDTSSQLKK 8.17 13.87 0.59 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 IYLQPGR 17.11 30.41 0.56 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 KLGSYEHR 3.86 7.12 0.54 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 LDQIESVITATSANTQLVLET 4.61 4.60 1.00 inhibitor heavy  LAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 LGSYEHR 3.06 4.94 0.62 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 LSNENHGIAQR 10.44 16.74 0.62 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 MATTMIQSK 20.18 33.27 0.61 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 MKQTVEAMK 4.20 7.89 0.53 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 NDLISATK 11.30 17.66 0.64 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 NVKENIQDNISLFSLGMGFD 0.18 inhibitor heavy  VDYDFLKR chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 NVQFNYPHTSVTDVTQNNF 6.10 9.78 0.62 inhibitor heavy  HNYFGGSEIVVAGK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 PSGGTNINEALLR 1.96 4.07 0.48 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 SSALDMENFR 29.97 50.84 0.59 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 SSALDMENFR 0.20 0.32 0.62 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 TAGLVR 5.34 9.84 0.54 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 TEVNVLPGAK 29.65 49.53 0.60 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 TILDDLRAEDHFSVIDFNQNI 29.54 49.72 0.59 inhibitor heavy  R chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 TWRNDLISATK 2.54 4.23 0.60 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 VQFELHYQEVK 10.70 23.59 0.45 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 VQSTITSR 15.02 25.32 0.59 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 VVNNSPQPQNVVFDVQIPK 17.70 31.88 0.56 inhibitor heavy  chain H2 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8 AREEHRIPER 0.21 0.57 0.36 alpha-trypsin inhibitor  heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8 ESPGNVQIVNGYFVHFFAPQ 0.48 0.56 0.86 alpha-trypsin inhibitor  GLPVVPK heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8 MSAQTHGLLGQFFQPFDFK 0.35 alpha-trypsin inhibitor  heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8 SMEDKGMTNINDGLLR 0.15 0.78 0.19 alpha-trypsin inhibitor  heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8 TAGLVK 4.87 7.26 0.67 alpha-trypsin inhibitor  heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8 VSDIRPGSDPTKPDATLVVK 0.66 alpha-trypsin inhibitor  heavy chain H3 ITIH4 Isoform 1 of Inter- IPI:IPI00294193.4 FAHTVVTSR 35.36 43.76 0.81 alpha-trypsin inhibitor  heavy chain H4 ITIH4 Isoform 1 of Inter- IPI:IPI00294193.4 ILDDLSPR 41.07 49.94 0.82 alpha-trypsin inhibitor  heavy chain H4 ITIH4 Isoform 1 of Inter- IPI:IPI00294193.4 NVVFVIDK 27.71 34.54 0.80 alpha-trypsin inhibitor  heavy chain H4 ITIH4 Isoform 1 of Inter- IPI:IPI00294193.4 SAGLVK 5.38 6.71 0.80 alpha-trypsin inhibitor  heavy chain H4 KIAA0423 Isoform 1 of IPI:IPI00744872.2 LHDSNSK 0.23 Uncharacterized protein KIAA0423 KLKB1 Plasma kallikrein IPI:IPI00654888.4 YSPGGTPTAIK 2.25 3.35 0.67 KNG1 Kininogen-1 IPI:IPI00032328.2 AATGECTATVGKR 0.38 0.72 0.53 KNG1 Kininogen-1 IPI:IPI00032328.2 AVDAALKK 18.44 29.10 0.63 KNG1 Kininogen-1 IPI:IPI00032328.2 DIPTNSPELEETLTHTITK 47.87 61.90 0.77 KNG1 Kininogen-1 IPI:IPI00032328.2 KYFIDFVAR 18.42 24.78 0.74 KNG1 Kininogen-1 IPI:IPI00032328.2 QVVAGLNFR 23.86 34.40 0.69 KNG1 Isoform HMW of IPI:IPI00032328.2 SVSEINPTTQMK 0.20 0.42 0.49 Kininogen-1 KNG1 Kininogen-1 IPI:IPI00032328.2 YFIDFVAR 28.85 40.11 0.72 KRT10 Keratin, type I  IPI:IPI00009865.2 GSLGGGFSSGGFSGGSFSR 2.13 cytoskeletal 10 KRT10 Keratin, type I  IPI:IPI00009865.2 SKELTTEIDNNIEQISSYK 3.04 3.69 0.83 cytoskeletal 10 KRT10 Keratin, type I  IPI:IPI00009865.2 VTMQNLNDR 1.07 0.19 5.65 cytoskeletal 10 KRT2 Keratin, type II  IPI:IPI00021304.1 NLDLDSIIAEVKAQYEEIAQ 3.75 cytoskeletal R 2 epidermal KRT2 Keratin, type II  IPI:IPI00021304.1 VDLLNQEIEFLK 1.00 cytoskeletal 2 epidermal LBP Lipopolysaccharide- IPI:IPI00032311.4 ATAQMLEVMFK 0.88 binding protein LBP Lipopolysaccharide- IPI:IPI00032311.4 GLQYAAQEGLLALQSELLR 0.36 binding protein LBP Lipopolysaccharide- IPI:IPI00032311.4 ITGFLKPGK 0.61 binding protein LBP Lipopolysaccharide- IPI:IPI00032311.4 ITLPDFTGDLR 1.32 binding protein LBP Lipopolysaccharide- IPI:IPI00032311.4 SFRPFVPR 0.59 binding protein LBP Lipopolysaccharide- IPI:IPI00032311.4 SPVTLLAAVMSLPEEHNK 0.70 binding protein LCP1 Plastin-2 IPI:IPI00010471.5 FSLVGIGGQDLNEGNR 0.43 LCP1 Plastin-2 IPI:IPI00010471.5 IKVPVDWNR 0.27 LCP1 Plastin-2 IPI:IPI00010471.5 QFVTATDVVR 0.49 LDHB L-lactate   IPI:IPI00219217.3 GLTSVINQK 0.47 0.29 1.64 dehydrogenase B chain LDHB L-lactate   IPI:IPI00219217.3 IVADKDYSVTANSK 0.16 0.06 2.44 dehydrogenase B chain LIFR Leukemia inhibitory  IPI:IPI00444272.2 QFLIPPK 409.27 695.10 0.59 factor receptor LPA Apolipoprotein IPI:IPI00029168.1 GTLSTTITGR 0.37 0.36 1.01 LPA Apolipoprotein IPI:IPI00029168.1 GTYSTTVTGR 1.57 5.41 0.29 LRG1 Leucine-rich alpha-2- IPI:IPI00022417.4 LGHLDLSGNR 0.25 0.22 1.13 glycoprotein LUM Lumican IPI:IPI00020986.2 FNALQYLR 2.01 4.54 0.44 LUM Lumican IPI:IPI00020986.2 LKEDAVSAAFK 6.20 12.80 0.48 LUM Lumican IPI:IPI00020986.2 LPSGLPVSLLTLYLDNNK 1.43 3.74 0.38 LUM Lumican IPI:IPI00020986.2 NIPTVNENLENYYLEVNQLE 0.94 2.93 0.32 K LUM Lumican IPI:IPI00020986.2 NNQIDHIDEK 0.22 0.61 0.37 LUM Lumican IPI:IPI00020986.2 SLEDLQLTHNK 6.71 13.68 0.49 LUM Lumican IPI:IPI00020986.2 SLEYLDLSFNQIAR 2.86 6.69 0.43 LUM Lumican IPI:IPI00020986.2 SVPMVPPGIK 2.29 4.55 0.50 MASP1 mannan-binding lectin IPI:IPI00290283.6 TLSDVLQYVK 0.18 0.29 0.64 serine protease 1  isoform 2 MBL2 Mannose-binding  IPI:IPI00004373.1 FQASVATPR 4.84 2.46 1.97 protein C MCAM Isoform 1 of Cell  IPI:IPI00016334.2 IFLCQGK 2.53 1.50 1.68 surface glycoprotein MUC18 MED12L Isoform 4 of Mediator  IPI:IPI00044353.6 LDPAGSFVPTNTK 0.41 of RNA polymerase II transcription subunit  12-like protein MEGF8 Isoform 1 of Multiple IPI:IPI00027310.4 SFHAAAYVPAGR 5.16 8.22 0.63 epidermal growth  factor-like  domains 8 MMP8 Neutrophil collagenase IPI:IPI00027846.1 YYAFDLIAQR 0.45 MSN Moesin IPI:IPI00219365.3 IGFPWSEIR 0.27 MTMR15 Isoform 1 of  IPI:IPI00007317.4 RLEPTIK 27.01 34.25 0.79 Coiled-coil domain-containing protein MTMR15 MYCBP2 Putative uncharacterized IPI:IPI00383833.1 KECEKENK 1.11 protein DKFZp586G0322 (Fragment) NRCAM Isoform 1 of Neuronal  IPI:IPI00333776.5 DSTGTYTCVAR 0.16 cell adhesion molecule NRP1 Neuropilin 1 IPI:IPI00398715.5 IKPATWETGISMR 0.33 OLFM1 Isoform 1 of Noelin IPI:IPI00017841.2 VSNLEER 1.10 1.90 0.58 ORM1 Alpha-l-acid  IPI:IPI00022429.3 YVGGQEHFAHLLILR 2.42 3.78 0.64 glycoprotein 1 PCSK9 Isoform 1 of Proprotein IPI:IPI00387168.1 VMVTDFENVPEEDGTR 0.67 0.33 2.00 convertase subtilisin/ kexin type 9 PCYOX1 Prenylcysteine  IPI:IPI00384280.5 LFLSYDYAVK 0.11 oxidase 1 PDIA3 Protein disulfide- IPI:IPI00025252.1 ELSDFISYLQR 0.23 isomerase A3 PDIA3 Protein disulfide- IPI:IPI00025252.1 TFSHELSDFGLESTAGEIPVV 0.23 isomerase A3 AIR PDIA3 Protein disulfide- IPI:IPI00025252.1 YGVSGYPTLK 0.33 0.45 0.72 isomerase A3 PEBP4 PEBP family protein IPI:IPI00163563.3 HWLVTDIK 0.37 PFN1 Profilin-1 IPI:IPI00216691.5 DSLLQDGEFSMDLR 1.52 1.28 1.19 PGLYRP2 N-acetylmuramoyl-L- IPI:IPI00163207.1 AGLLRPDYALLGHR 2.21 3.02 0.73 alanine amidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1 EGKEYGVVLAPDGSTVAVE 1.60 3.38 0.47 acetylmuramoyl-L-alanine PLLAGLEAGLQGR amidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1 RVINLPLDSMAAPWETGDT 0.81 0.86 0.94 acetylmuramoyl-L-alanine FPDVVAIAPDVR amidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1 TFTLLDPK 3.40 6.16 0.55 acetylmuramoyl-L-alanine amidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1 WGAAPYR 0.73 0.57 1.27 acetylmuramoyl-L-alanine amidase PI16 Isoform 1 of Peptidase IPI:IPI00301143.5 AQVSPTASDMLHMR 0.37 inhibitor 16 PI16 Isoform 1 of Peptidase IPI:IPI00301143.5 LMVELHNLYR 0.19 0.68 0.27 inhibitor 16 PLEK Pleckstrin IPI:IPI00306311.8 NRQEGLMIASSLLNEGYLQP 0.32 0.53 0.60 AGDMSK PNP Purine nucleoside IPI:IPI00871140.1 VIMDYESLEK 0.16 phosphorylase PODXL Podocalyxin-like  IPI:IPI00299116.1 EITIHTK 0.47 0.82 0.57 protein 1 POLR2A DNA-directed RNA IPI:IPI00031627.3 MDDDVFLRCIESNMLTDMT 0.27 polymerase II subunit LQGI RPB1 POSTN Isoform 1 of Periostin IPI:IPI00007960.4 DGHFTLFAPTNEAFEK 3.19 5.78 0.55 PPAN Protein IPI:IPI00853545.1 RRWSTR 0.17 0.36 0.46 PPBP Platelet basic protein IPI:IPI00022445.1 DSDLYAELR 0.42 0.19 2.17 PRDX2 Peroxiredoxin-2 IPI:IPI00027350.3 IGKPAPDFK 0.64 PRDX2 Peroxiredoxin-2 IPI:IPI00027350.3 QITVNDLPVGR 0.47 PROZ Isoform 1 of Vitamin  IPI:IPI00027843.1 RAPDLQDLPWQVK 0.21 0.33 0.63 K-dependent protein Z PSAT1 Isoform 1 of  IPI:IPI00001734.2 FGTINIVHPK 0.30 Phosphoserine aminotransferase PSMB2 Proteasome subunit beta IPI:IPI00028006.1 NGYELSPTAAANFTR 0.15 type-2 PTCHD2 Isoform 2 of Patched IPI:IPI00002283.8 ETPPLEDLAANQSEDPRNQR 0.14 domain-containing  LSK protein 2 PTGDS Prostaglandin-H2 D- IPI:IPI00013179.1 APEAQVSVQPNFQQDK 5.15 isomerase PVR Isoform Beta of  IPI:IPI00219425.3 VLAKPQNTAEVQK 0.09 Poliovirus receptor PZP Pregnancy zone protein IPI:IPI00025426.2 AFQPFFVELTMPYSVIR 7.72 0.32 24.32 PZP Pregnancy zone protein IPI:IPI00025426.2 ATVLNYLPK 7.93 0.43 18.58 PZP Pregnancy zone protein IPI:IPI00025426.2 QGIPFFAQVLLVDGK 0.12 PZP Pregnancy zone protein IPI:IPI00025426.2 VVVQTESGGR 0.08 QSOX1 Isoform 1 of Sulfhydryl IPI:IPI00003590.2 VLNTEANVVR 0.07 oxidase 1 RBP4 Plasma retinol-binding IPI:IPI00022420.3 FSGTWYAMAK 0.59 protein RBP4 Plasma retinol-binding IPI:IPI00022420.3 LIVHNGYCDGR 0.29 protein RBP4 Plasma retinol-binding IPI:IPI00022420.3 MKYWGVASFLQK 2.10 protein RELN reelin isoform a IPI:IPI00241562.4 TSGITCIKPR 0.67 RERE Isoform 1 of Arginine- IPI:IPI00185027.4 KVKEEASSPLK 0.12 glutamic acid dipeptide repeats protein SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4 EANYIGSDK 1.45 0.77 1.89 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 EANYIGSDK 1.45 0.77 1.89 SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4 EANYIGSDKYFHAR 2.19 1.22 1.80 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 EANYIGSDKYFHAR 2.19 1.22 1.80 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 FFGHGAEDSLADQAANEW 4.65 1.07 4.34 GR SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4 FFSFLGEAFDGAR 2.62 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 FFSFLGEAFDGAR 2.62 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 RGPGGVWAAEAISDAR 4.82 4.49 1.07 SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4 RSFFSFLGEAFDGAR 3.01 2.41 1.25 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 RSFFSFLGEAFDGAR 3.01 2.41 1.25 SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4 SFFSFLGEAFDGAR 8.44 6.76 1.25 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 SFFSFLGEAFDGAR 8.44 6.76 1.25 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 SGKDPNHFRPAGLPEKY 5.36 SAA4 Serum amyloid  IPI:IPI00019399.1 EALQGVGDMGR 11.54 7.35 1.57 A-4 protein SAA4 Serum amyloid  IPI:IPI00019399.1 VYLQGLIDYYLFGNSSTVLE 0.56 0.19 2.92 A-4 protein DSK SCML2 Isoform 1 of Sex comb  IPI:IPI00328688.3 LDGSDNR 0.32 0.69 0.46 on midleg-like  protein 2 SELENBP1 Selenium-binding  IPI:IPI00012303.2 HNVMISTEWAAPNVLR 0.28 0.48 0.58 protein 1 SEMA7A Semaphorin-7A IPI:IPI00025257.1 LQDVFLLPDPSGQWR 0.58 SEPP1 Selenoprotein P IPI:IPI00029061.2 LPTDSELAPR 1.51 2.10 0.72 SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 GKWERPFEVK 56.93 25.11 2.27 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 GTEAAGAMFLEAIPM 17.00 7.28 2.33 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 GTEAAGAMFLEAIPM 0.42 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 KLSSWVLLMK 49.95 17.92 2.79 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 KLSSWVLLMK 2.15 0.89 2.42 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 KQINDYVEKGTQGK 0.59 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 LAEFAFSLYR 12.97 5.48 2.37 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 LYHSEAFTVNFGDTEEAKK 6.55 antitrypsin QINDYVEK SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 PFVFLMIEQNTK 0.43 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 TVNFGDTEEAKK 1.01 1.16 0.86 antitrypsin SERPINA10 Protein Z-dependent IPI:IPI00007199.4 NMEVFFPK 0.27 protease inhibitor SERPINA3 Alpha-l-antichymotrypsin IPI:IPI00550991.3 FEEGTEASAATAVK 0.48 SERPINA3 Alpha-l-antichymotrypsin IPI:IPI00550991.3 IIVPTDTQNIFFMSK 1.20 1.08 1.11 SERPINA3 Alpha-l-antichymotrypsin IPI:IPI00550991.3 PFDPQDTHQSR 1.66 0.62 2.66 SERPINA3 Alpha-l-antichymotrypsin IPI:IPI00550991.3 WVMVPMMSLHHLTIPYFR 0.44 SERPINA4 Kallistatin IPI:IPI00328609.3 ATLDVDEAGTEAAAATSFAI 0.47 0.48 1.00 K SERPINA4 Kallistatin IPI:IPI00328609.3 FYYLIASETPGK 1.57 1.70 0.93 SERPINA4 Kallistatin IPI:IPI00328609.3 LGFTDLFSK 3.25 5.05 0.64 SERPINA4 Kallistatin IPI:IPI00328609.3 WADLSGITK 1.79 1.91 0.94 SERPINA7 Thyroxine-binding IPI:IPI00292946.1 FAFNLYR 7.38 10.02 0.74 globulin SERPINC1 SERPINC1 protein IPI:IPI00844156.2 FATTFYQHLADSKNDNDNIF 0.21 LSPLSISTAFAMTK SERPINC1 Antithrombin III  IPI:IPI00032179.2 FATTFYQHLADSKNDNDNIF 0.21 variant LSPLSISTAFAMTK SERPINC1 SERPINC1 protein IPI:IPI00844156.2 LVSANR 5.73 8.06 0.71 SERPINC1 Antithrombin III  IPI:IPI00032179.2 LVSANR 5.73 8.06 0.71 variant SERPINC1 SERPINC1 protein IPI:IPI00844156.2 RVWELSK 36.77 46.37 0.79 SERPINC1 Antithrombin III  IPI:IPI00032179.2 RVWELSK 36.77 46.37 0.79 variant SERPINC1 Antithrombin III  IPI:IPI00032179.2 VAEGTQVLELPFKGDDITM 0.59 1.01 0.58 variant VLILPKPEK SERPIND1 Serpin peptidase  IPI:IPI00292950.4 FAFNLYR 7.38 10.02 0.74 inhibitor, clade D (Heparin  cofactor), member 1 SERPIND1 Serpin peptidase  IPI:IPI00292950.4 SVNDLYIQK 9.13 12.01 0.76 inhibitor, clade D (Heparin  cofactor), member 1 SERPINF1 Pigment epithelium- IPI:IPI00006114.4 LQSLFDSPDFSK 8.16 11.20 0.73 derived factor SERPINF1 Pigment epithelium- IPI:IPI00006114.4 TVQAVLTVPK 5.46 7.34 0.74 derived factor SERPINF1 Pigment epithelium- IPI:IPI00006114.4 TVRVPMMSDPK 0.27 0.48 0.57 derived factor SERPINF2 Alpha-2-antiplasmin IPI:IPI00879231.1 DFLQSLK 0.81 1.36 0.60 SERPINF2 Alpha-2-antiplasmin IPI:IPI00879231.1 GDKLFGPDLK 14.71 59.89 0.25 SERPINF2 Alpha-2-antiplasmin IPI:IPI00879231.1 IQEFLSGLPEDTVLLLLNAIH 1.79 2.33 0.77 FQGFWR SERPING1 Plasma protease C1 IPI:IPI00291866.5 MEPFHFKNSVIKVPMMNSK 0.32 0.62 0.52 inhibitor SERPING1 Plasma protease C1 IPI:IPI00291866.5 PVAHFIDQTLK 0.70 inhibitor SERPING1 Plasma protease C1 IPI:IPI00291866.5 VATTVISK 0.99 1.68 0.59 inhibitor SH3BGRL2 SH3 domain-binding IPI:IPI00412272.2 ESNTVFSFLGLKPR 0.89 glutamic acid-rich-like protein 2 SH3BGRL3 SH3 domain-binding IPI:IPI00746352.1 VYSTSVTGSR 0.25 0.22 1.14 glutamic acid-rich-like protein 3 SHBG Isoform 1 of Sex  IPI:IPI00023019.1 IALGGLLFPASNLR 0.81 1.62 0.50 hormone-binding  globulin SHBG Isoform 1 of Sex  IPI:IPI00023019.1 TSSSFEVR 0.16 0.39 0.42 hormone-binding  globulin SHBG Isoform 1 of Sex  IPI:IPI00023019.1 VVLSSGSGPGLDLPLVLGLP 0.41 0.97 0.42 hormone-binding  LQLK globulin SLC14A2 Urea transporter,  IPI:IPI00177820.3 ASIITK 0.72 0.95 0.75 kidney SLC9A6 Sodium/hydrogen IPI:IPI00022061.5 LLNLGR 0.43 exchanger 6 SMG7 Breast cancer-associated IPI:IPI00871896.1 MSFLGILCK 0.16 0.14 1.17 antigen SGA-56M SVIL Isoform 2 of  IPI:IPI00018370.3 RSRNTAVEQRLR 0.50 Supervillin TAGLN2 Transgelin-2 IPI:IPI00550363.3 DVGRPQPGRENFQNWLK 0.27 TAOK1 Isoform 1 of IPI:IPI00002232.2 VSLRRALLEQK 7.19 9.27 0.78 Serine/threonine-protein kinase TAO1 TEGT Bax inhibitor 1 IPI:IPI00022748.4 KLMMILAMNEKDK 0.25 TF Serotransferrin IPI:IPI00022463.1 HQTVPQNTGGK 1.02 TF Serotransferrin IPI:IPI00022463.1 SDNCEDTPEAGYFAVAVVK 1.38 K TF Serotransferrin IPI:IPI00022463.1 YLGEEYVK 4.05 THBS1 Thrombospondin-1 IPI:IPI00296099.6 DLASIAR 0.57 5.76 0.10 THBS1 Thrombospondin-1 IPI:IPI00296099.6 FVFGTTPEDILR 1.87 1.11 1.68 THBS1 Thrombospondin-1 IPI:IPI00296099.6 GTLLALERK 0.58 0.95 0.61 TIMP1 Metalloproteinase  IPI:IPI00032292.1 HLACLPR 0.39 3.64 0.11 inhibitor 1 TKT Transketolase IPI:IPI00643920.2 MFGIDRDAIAQAVR 0.73 TLN1 Talin-1 IPI:IPI00298994.6 ALSTDPAAPNLK 2.29 0.50 4.58 TLN1 Talin-1 IPI:IPI00298994.6 AVASAAAALVLK 0.91 0.36 2.56 TLN1 Talin-1 IPI:IPI00298994.6 LASEAKPAAVAAENEEIGSH 0.91 IK TLN1 Talin-1 IPI:IPI00298994.6 VLVQNAAGSQEK 0.64 0.29 2.24 TLN1 Talin-1 IPI:IPI00298994.6 VMVTNVTSLLK 1.81 0.82 2.21 TNC Isoform 1 of Tenascin IPI:IPI00031008.1 KQSEPLEITLLAPER 3.50 33.66 0.10 TPM2 Tropomyosin 2 IPI:IPI00513698.1 IQLVEEELDRAQER 0.63 0.30 2.10 TTR Transthyretin IPI:IPI00022432.1 AADDTWEPFASGK 84.06 151.87 0.55 TTR Transthyretin IPI:IPI00022432.1 ADDTWEPFASGK 0.29 0.48 0.60 UBA1 Ubiquitin-like modifier- IPI:IPI00645078.1 KPLLESGTLGTK 0.42 activating enzyme 1 UBE2L3 Ubiquitin-conjugating IPI:IPI00021347.1 TDQVIQSLIALVNDPQPEHPL 34.09 enzyme E2 L3 R VASN Vasorin IPI:IPI00395488.2 YLQGSSVQLR 0.21 VCL Isoform 1 of Vinculin IPI:IPI00291175.7 AQQVSQGLDVLTAK 0.81 0.38 2.14 VCL Isoform 1 of Vinculin IPI:IPI00291175.7 MSAEINEIIR 0.33 0.55 0.60 VNN1 Pantetheinase IPI:IPI00030871.2 AFHYDMK 0.63 VTN Vitronectin IPI:IPI00298971.1 GQYCYELDEK 0.32 VTN Vitronectin IPI:IPI00298971.1 LIRDVWGIEGPIDAAFTR 0.74 VWF von Willebrand factor IPI:IPI00023014.1 HIVTFDGQNFK 1.08 0.70 1.55 VWF von Willebrand factor IPI:IPI00023014.1 VIVIPVGIGPHANLK 0.92 0.62 1.50 VWF von Willebrand factor IPI:IPI00023014.1 YIILLLGK 0.51 YWHAB Isoform Short of 14-3-3 IPI:IPI00759832.1 YDDMAAAMK 0.25 protein beta/alpha YWHAG 14-3-3 protein gamma IPI:IPI00220642.7 YDDMAAAMK 0.25

TABLE S2 Identified significant proteins Average Average Ratio HL GENE #peptides/ HL HL positive/HL SYMBOL Description protein Reference positive negative negative A1BG Alpha-1B-glycoprotein precursor 27 IPI: IPI00022895.7 23.54 24.48 0.96 ACTA1 Actin, alpha skeletal muscle 19 IPI: IPI00021428.1 3.34 6.23 0.54 ACTB Actin, cytoplasmic 1 25 IPI: IPI00021439.1 4.79 4.32 1.11 ACTN1 Alpha-actinin-1 21 IPI: IPI00013508.5 0.79 0.46 1.70 AGT Angiotensinogen precursor 23 IPI: IPI00032220.3 7.24 9.55 0.76 AHSG Alpha-2-HS-glycoprotein precursor 11 IPI: IPI00022431.1 27.46 16.07 1.71 AMBP AMBP protein precursor 6 IPI: IPI00022426.1 7.03 15.78 0.45 ANPEP Aminopeptidase N 5 IPI: IPI00221224.6 0.59 0.74 0.80 APOA4 Apolipoprotein A-IV precursor 42 IPI: IPI00304273.2 4.36 4.16 1.05 APOB Apolipoprotein B-100 precursor 320 IPI: IPI00022229.1 8.33 8.67 0.96 APOC1 Apolipoprotein C-I precursor 6 IPI: IPI00021855.1 1.75 0.35 5.04 APOC2 Apolipoprotein C-II precursor 9 IPI: IPI00021856.3 4.94 2.50 1.97 APOC3 Apolipoprotein C-III precursor 9 IPI: IPI00021857.1 3.58 2.86 1.25 APOE Apolipoprotein E precursor 25 IPI: IPI00021842.1 3.79 1.83 2.07 APOF apolipoprotein F precursor 2 IPI: IPI00299435.3 1.38 0.36 3.85 APOH Beta-2-glycoprotein 1 precursor 7 IPI: IPI00298828.3 17.52 14.91 1.18 APOL1 42 kDa protein 9 IPI: IPI00852826.2 0.58 0.71 0.81 APOM Apolipoprotein M 3 IPI: IPI00030739.1 2.25 1.51 1.49 ARHGDIB Rho GDP-dissociation inhibitor 2 4 IPI: IPI00003817.3 0.28 2.06 0.13 ASL Argininosuccinate lyase 2 IPI: IPI00220267.7 0.36 0.58 0.62 AZGP1 alpha-2-glycoprotein 1, zinc 15 IPI: IPI00166729.4 7.06 11.59 0.61 B2M Beta-2-microglobulin 5 IPI: IPI00868938.1 1.08 1.77 0.61 BCHE Cholinesterase precursor 13 IPI: IPI00025864.5 1.06 0.67 1.58 BLVRB Flavin reductase 2 IPI: IPI00783862.2 0.39 0.51 0.76 BTD biotinidase precursor 8 IPI: IPI00218413.2 0.67 0.88 0.77 C1QA Complement C1q subcomponent subunit A 3 IPI: IPI00022392.1 1.03 1.17 0.88 precursor C1QB complement component 1, q subcomponent, 5 IPI: IPI00477992.1 0.96 0.66 1.47 B chain precursor C1R Complement C1r subcomponent precursor 13 IPI: IPI00296165.5 1.02 0.90 1.13 C1RL Complement C1r-like protein 9 IPI: IPI00009793.3 0.32 0.40 0.80 C1S Complement C1s subcomponent precursor 18 IPI: IPI00017696.1 1.09 1.21 0.91 C2 Complement C2 precursor (Fragment) 27 IPI: IPI00303963.1 1.64 1.45 1.13 C3 Complement C3 precursor (Fragment) 216 IPI: IPI00783987.2 16.75 16.37 1.02 C4A Complement component 4A 126 IPI: IPI00643525.1 13.88 10.76 1.29 C4B C4B1 128 IPI: IPI00418163.3 18.80 12.78 1.47 C4BPA C4b-binding protein alpha chain precursor 9 IPI: IPI00021727.1 0.52 0.48 1.08 C5 Complement C5 precursor 76 IPI: IPI00032291.2 2.48 2.95 0.84 C6 Complement component 6 precursor 25 IPI: IPI00009920.2 1.08 1.29 0.84 C7 Complement component C7 precursor 21 IPI: IPI00296608.6 1.36 1.48 0.92 C8A Complement component C8 alpha chain 18 IPI: IPI00011252.1 1.72 2.91 0.59 precursor C8B Complement component C8 beta chain 18 IPI: IPI00294395.1 2.12 1.95 1.09 precursor C9 Complement component C9 precursor 24 IPI: IPI00022395.1 3.44 3.14 1.10 CA1 Carbonic anhydrase 1 6 IPI: IPI00215983.3 1.32 1.21 1.09 CD14 Monocyte differentiation antigen CD14 7 IPI: IPI00029260.2 0.39 0.27 1.46 precursor CDH5 Cadherin-5 precursor 2 IPI: IPI00012792.1 0.37 0.27 1.39 CECR1 Cat eye syndrome critical region protein 1 2 IPI: IPI00303071.4 5.31 0.63 8.40 precursor CFB Isoform 1 of Complement factor B precursor 43 IPI: IPI00019591.1 10.49 9.81 1.07 (Fragment) CFD Complement factor D preproprotein 4 IPI: IPI00165972.3 0.28 1.40 0.20 CFH Isoform 1 of Complement factor H precursor 28 IPI: IPI00029739.5 4.04 4.34 0.93 CFI Complement factor I precursor 13 IPI: IPI00291867.3 2.04 2.55 0.80 CFL1 Cofilin-1 6 IPI: IPI00012011.6 0.51 0.51 1.00 CLEC3B Tetranectin precursor 6 IPI: IPI00009028.1 1.26 1.01 1.26 CNDP1 Beta-Ala-His dipeptidase precursor 21 IPI: IPI00064667.4 0.44 0.44 1.00 CNTN1 Isoform 1 of Contactin-1 precursor 2 IPI: IPI00029751.1 1.15 0.49 2.36 COL6A3 alpha 3 type VI collagen isoform 1 precursor 3 IPI: IPI00022200.2 0.58 24.55 0.02 CP Ceruloplasmin precursor 78 IPI: IPI00017601.1 6.40 6.07 1.05 CPB2 Isoform 1 of Carboxypeptidase B2 precursor 13 IPI: IPI00329775.7 0.71 0.83 0.85 CPN1 Carboxypeptidase N catalytic chain 10 IPI: IPI00010295.1 0.54 0.65 0.83 precursor CPN2 similar to Carboxypeptidase N subunit 2 14 IPI: IPI00738433.1 1.43 1.60 0.89 precursor CRP Isoform 1 of C-reactive protein precursor 9 IPI: IPI00022389.1 15.24 3.24 4.71 CST3 Cystatin-C precursor 3 IPI: IPI00032293.1 1.64 1.04 1.57 ECM1 Extracellular matrix protein 1 10 IPI: IPI00645849.1 0.36 0.38 0.93 EFEMP1 Isoform 1 of EGF-containing fibulin-like 4 IPI: IPI00029658.1 0.21 0.41 0.53 extracellular matrix protein 1 precursor F10 Coagulation factor X precursor 9 IPI: IPI00019576.1 0.82 1.19 0.69 F11 Isoform 1 of Coagulation factor XI 8 IPI: IPI00008556.1 0.24 0.26 0.93 precursor F2 Prothrombin precursor (Fragment) 20 IPI: IPI00019568.1 6.98 6.10 1.14 F5 Coagulation factor V 14 IPI: IPI00022937.4 0.42 0.34 1.26 FCGBP IgGFc-binding protein precursor 4 IPI: IPI00242956.4 1.88 1.55 1.21 FCN3 Isoform 1 of Ficolin-3 precursor 9 IPI: IPI00293925.2 3.78 4.00 0.94 FGA Isoform 1 of Fibrinogen alpha chain 41 IPI: IPI00021885.1 2.55 0.96 2.65 precursor FLNA filamin A, alpha isoform 1 48 IPI: IPI00302592.2 0.51 0.42 1.22 FN1 Isoform 1 of Fibronectin precursor 19 IPI: IPI00022418.1 0.37 0.40 0.93 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 7 IPI: IPI00219018.7 0.93 1.06 0.88 GC Vitamin D-binding protein precursor 32 IPI: IPI00555812.4 13.45 10.90 1.23 GGH Gamma-glutamyl hydrolase precursor 4 IPI: IPI00023728.1 5.74 4.71 1.22 GP1BA platelet glycoprotein Ib alpha polypeptide 5 IPI: IPI00748955.2 0.52 0.67 0.78 precursor GPLD1 Isoform 1 of Phosphatidylinositol-glycan- 11 IPI: IPI00299503.2 2.04 0.35 5.77 specific phospholipase D precursor GSN Isoform 1 of Gelsolin precursor 44 IPI: IPI00026314.1 1.64 2.84 0.58 HBA2 Hemoglobin subunit alpha 9 IPI: IPI00410714.5 4.71 4.25 1.11 HGFAC Hepatocyte growth factor activator precursor 5 IPI: IPI00029193.1 0.42 0.42 1.01 HPR Isoform 1 of Haptoglobin-related protein 15 IPI: IPI00477597.1 1.73 1.72 1.01 precursor HPX Hemopexin precursor 39 IPI: IPI00022488.1 12.50 13.53 0.92 HRG Histidine-rich glycoprotein precursor 21 IPI: IPI00022371.1 7.89 9.94 0.79 HSPA8 Heat shock 70 kDa protein 8 isoform 2 7 IPI: IPI00795040.1 0.50 0.52 0.98 variant (Fragment) ICAM1 Intercellular adhesion molecule 1 precursor 3 IPI: IPI00008494.4 0.80 0.62 1.28 IGFALS Insulin-like growth factor-binding protein 20 IPI: IPI00020996.3 1.01 1.12 0.90 complex acid labile chain precursor IGFBP2 Insulin-like growth factor-binding protein 2 2 IPI: IPI00297284.1 0.28 0.17 1.68 precursor IGFBP6 Insulin-like growth factor-binding protein 6 2 IPI: IPI00029235.1 0.26 0.25 1.04 precursor ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 38 IPI: IPI00292530.1 4.28 5.84 0.73 precursor ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 62 IPI: IPI00305461.2 5.39 7.95 0.68 precursor ITIH3 Isoform 1 of Inter-alpha-trypsin inhibitor 28 IPI: IPI00028413.8 1.91 2.41 0.79 heavy chain H3 precursor ITIH4 Isoform 1 of Inter-alpha-trypsin inhibitor 53 IPI: IPI00294193.4 8.60 8.89 0.97 heavy chain H4 precursor KLKB1 Plasma kallikrein precursor 16 IPI: IPI00654888.4 1.73 1.99 0.87 KNG1 Kininogen-1 16 IPI: IPI00032328.2 17.24 21.46 0.80 KRT10 Keratin, type I cytoskeletal 10 9 IPI: IPI00009865.2 1.72 2.67 0.64 KRT2 Keratin, type II cytoskeletal 2 epidermal 4 IPI: IPI00021304.1 2.87 1.05 2.74 LBP Lipopolysaccharide-binding protein 8 IPI: IPI00032311.4 0.54 0.42 1.29 precursor LCP1 Plastin-2 7 IPI: IPI00010471.5 0.31 0.25 1.24 LDHB L-lactate dehydrogenase B chain 9 IPI: IPI00219217.3 1.92 0.92 2.08 LPA Apolipoprotein 11 IPI: IPI00029168.1 0.44 0.61 0.72 LRG1 Leucine-rich alpha-2-glycoprotein precursor 12 IPI: IPI00022417.4 15.44 11.60 1.33 LUM Lumican precursor 11 IPI: IPI00020986.2 1.82 4.43 0.41 MASP1 mannan-binding lectin serine protease 1 5 IPI: IPI00290283.6 0.25 0.43 0.57 isoform 2 precursor MBL2 Mannose-binding protein C precursor 5 IPI: IPI00004373.1 1.26 0.43 2.97 MCAM Isoform 1 of Cell surface glycoprotein 2 IPI: IPI00016334.2 2.49 1.39 1.79 MUC18 precursor MSN Moesin 4 IPI: IPI00219365.3 1.90 0.62 3.07 MTMR15 Isoform 1 of Coiled-coil domain-containing 2 IPI: IPI00007317.4 9.30 8.88 1.05 protein MTMR15 PCYOX1 Prenylcysteine oxidase 1 precursor 2 IPI: IPI00384280.5 0.19 0.21 0.90 PDIA3 Protein disulfide-isomerase A3 precursor 4 IPI: IPI00025252.1 0.27 0.40 0.68 PFN1 Profilin-1 9 IPI: IPI00216691.5 1.12 1.38 0.81 PGLYRP2 Isoform 1 of N-acetylmuramoyl-L-alanine 12 IPI: IPI00163207.1 1.19 2.02 0.59 amidase precursor PI16 Isoform 1 of Peptidase inhibitor 16 3 IPI: IPI00301143.5 0.60 0.41 1.48 precursor PLEK Pleckstrin 5 IPI: IPI00306311.8 0.53 0.52 1.01 PNP Purine nucleoside phosphorylase 2 IPI: IPI00871140.1 1.80 3.37 0.53 PPBP Platelet basic protein precursor 5 IPI: IPI00022445.1 0.62 0.38 1.63 PRDX2 Peroxiredoxin-2 4 IPI: IPI00027350.3 0.54 0.71 0.77 PROZ Isoform 1 of Vitamin K-dependent protein Z 3 IPI: IPI00027843.1 0.23 0.30 0.76 precursor PTGDS Prostaglandin-H2 D-isomerase precursor 3 IPI: IPI00013179.1 0.28 4.34 0.06 PVR Isoform Beta of Poliovirus receptor 2 IPI: IPI00219425.3 0.09 0.15 0.56 precursor PZP Pregnancy zone protein precursor 12 IPI: IPI00025426.2 0.55 0.26 2.15 QSOX1 Isoform 1 of Sulfhydryl oxidase 1 precursor 2 IPI: IPI00003590.2 0.37 0.12 3.13 RBP4 Plasma retinol-binding protein precursor 10 IPI: IPI00022420.3 8.57 6.59 1.30 RELN reelin isoform a 2 IPI: IPI00241562.4 0.84 0.88 0.94 SAA1 serum amyloid A2 7 IPI: IPI00006146.4 1.45 0.51 2.86 SAA2 Serum amyloid A protein precursor 8 IPI: IPI00552578.2 3.84 2.19 1.75 SAA4 Serum amyloid A-4 protein precursor 8 IPI: IPI00019399.1 1.20 0.93 1.29 SELENBP1 Selenium-binding protein 1 2 IPI: IPI00012303.2 11.85 20.47 0.58 SEMA7A Semaphorin-7A precursor 2 IPI: IPI00025257.1 2.02 1.15 1.76 SEPP1 Selenoprotein P precursor 3 IPI: IPI00029061.2 0.56 0.83 0.67 SERPINA10 Protein Z-dependent protease inhibitor 9 IPI: IPI00007199.4 0.33 0.29 1.14 precursor SERPINA3 Alpha-1-antichymotrypsin precursor 50 IPI: IPI00550991.3 18.18 16.80 1.08 SERPINA4 Kallistatin precursor 19 IPI: IPI00328609.3 1.09 1.50 0.73 SERPINA7 Thyroxine-binding globulin precursor 20 IPI: IPI00292946.1 2.09 1.89 1.11 SERPINC1 Antithrombin III variant 49 IPI: IPI00032179.2 7.26 7.87 0.92 SERPINC1 SERPINC1 protein 27 IPI: IPI00844156.2 4.65 4.06 1.14 SERPIND1 Serpin peptidase inhibitor, clade D (Heparin 22 IPI: IPI00292950.4 5.63 5.30 1.06 cofactor), member 1 SERPINF1 Pigment epithelium-derived factor precursor 27 IPI: IPI00006114.4 2.07 2.83 0.73 SERPINF2 Alpha-2-antiplasmin precursor 24 IPI: IPI00879231.1 6.34 6.17 1.03 SERPING1 Plasma protease C1 inhibitor precursor 42 IPI: IPI00291866.5 7.43 10.58 0.70 SHBG Isoform 1 of Sex hormone-binding globulin 10 IPI: IPI00023019.1 0.33 0.42 0.78 precursor TAGLN2 Transgelin-2 6 IPI: IPI00550363.3 0.42 0.31 1.36 THBS1 Thrombospondin-1 precursor 18 IPI: IPI00296099.6 0.49 0.37 1.31 TIMP1 Metalloproteinase inhibitor 1 precursor 2 IPI: IPI00032292.1 0.74 3.51 0.21 TLN1 Talin-1 40 IPI: IPI00298994.6 0.83 0.39 2.15 TNC Isoform 1 of Tenascin precursor 3 IPI: IPI00031008.1 0.91 0.94 0.97 TPM2 Tropomyosin 2 4 IPI: IPI00513698.1 0.37 0.32 1.17 TTR Transthyretin precursor 19 IPI: IPI00022432.1 6.96 9.74 0.71 VASN Vasorin precursor 3 IPI: IPI00395488.2 0.25 0.32 0.77 VCL Isoform 1 of Vinculin 20 IPI: IPI00291175.7 0.35 0.25 1.40 VTN Vitronectin precursor 15 IPI: IPI00298971.1 9.92 10.69 0.93 VWF von Willebrand factor precursor 25 IPI: IPI00023014.1 1.34 1.09 1.22 YWHAB Isoform Short of 14-3-3 protein beta/alpha 4 IPI: IPI00759832.1 0.28 0.23 1.22 YWHAG 14-3-3 protein gamma 4 IPI: IPI00220642.7 0.37 0.63 0.59

TABLE S3 Significantly altered proteins and related biological functions. Peptides were initially identified by mass spectrometry. Selected biological functions and expression sites associated with the individual proteins were identified by Ingenuity Pathway Analysis (IPA). Gene #pept/ Biological Expressed^(b) in Protein Symbol protein Ratio^(a) Function Liver WBC^(c) 14-3-3 protein gamma YWHAG 4 0.59 Cancer X Actin, alpha skeletal muscle ACTA1 19 0.54 X X Alpha 3 type VI collagen COL6A3 3 0.02 Cancer X X Alpha-2-glycoprotein 1, AZGP1 15 0.61 Cancer zinc Alpha-2-HS-glycoprotein AHSG 11 1.71 IR^(d), Cancer X Alpha-actinin-1 ACTN1 21 1.70 X AMBP protein AMBP 6 0.45 IR, Cancer X Apolipoprotein LPA 11 0.70 Apolipoprotein C-I APOC1 6 5.04 Cancer X X Apolipoprotein C-II APOC2 9 1.97 Apolipoprotein E APOE 25 2.07 IR, Cancer X apolipoprotein F APOF 2 3.85 Cancer X Apolipoprotein M APOM 3 1.50 X Argininosuccinate lyase ASL 2 0.62 X Beta-2-microglobulin B2M 5 0.61 IR, Cancer X X C4B1 C4B 128 1.50 IR, Cancer X Cat eye syndrome critical CECR1 2 8.40 region protein 1 Cell surface glycoprotein MCAM 2 1.79 IR, Cancer MUC18 Cholinesterase BCHE 13 1.58 Coagulation factor X F10 9 0.69 X Complement component 4A C4A 126 1.29 IR, Cancer X Complement component C8 C8A 18 0.59 IR X alpha chain Complement factor D CFD 4 0.20 IR, Cancer X preproprotein Contactin-1 CNTN1 2 2.36 C-reactive protein CRP 9 4.71 IR, Cancer X Cystatin-C CST3 3 1.57 Cancer X EGF-containing fibulin-like EFEMP1 4 0.53 Cancer X extracellular matrix protein 1 Gelsolin GSN 44 0.58 IR, Cancer Insulin-like growth factor- IGFBP2 2 1.68 Cancer X X binding protein 2 Inter-alpha-trypsin inhibitor ITIH1 38 0.70 X heavy chain H1 Inter-alpha-trypsin inhibitor ITIH2 62 0.70 X heavy chain H2 Phosphatidylinositol- GPLD1 11 5.77 X glycan-specific phospholipase D Sulfhydryl oxidase 1 QSOX1 2 3.13 X Kallistatin SERPINA4 19 0.70 Keratin, type I cytoskeletal KRT10 9 0.64 X X 10 Keratin, type II cytoskeletal KRT2 4 2.74 2 epidermal L-lactate dehydrogenase B LDHB 9 2.08 X chain Lumican LUM 11 0.41 IR X Mannan-binding lectin MASP1 5 0.57 IR, Cancer X serine protease 1 Mannose-binding protein C MBL2 5 2.97 IR Metalloproteinase inhibitor 1 TIMP1 2 0.21 IR, Cancer X X Moesin MSN 4 3.07 IR X Monocyte differentiation CD14 7 1.5 IR, Cancer X antigen CD14 Peptidase inhibitor 16 PI16 3 1.50 X Pigment epithelium-derived SERPINF1 27 0.70 X factor Plasma protease C1 SERPING1 42 0.70 X X inhibitor Platelet basic protein PPBP 5 1.63 IR X Poliovirus receptor PVR 2 0.56 IR X Pregnancy zone protein PZP 12 2.15 Prostaglandin-H2 D- PTGDS 3 0.06 IR, Cancer X isomerase Protein disulfide-isomerase PDIA3 4 0.68 X A3 Purine nucleoside PNP 2 0.53 IR, Cancer X phosphorylase Rho GDP-dissociation ARHGDIB 4 0.13 IR, Cancer X X inhibitor 2 Selenium-binding protein 1 SELENBP1 2 0.58 Cancer Selenoprotein P SEPP1 3 0.70 X X Semaphorin-7A/CD108 SEMA7A 2 1.76 IR X Serum amyloid A SAA2 8 1.75 X X Serum amyloid A2 SAA1 7 2.86 IR, Cancer X X Talin-1 TLN1 40 2.15 X Transthyretin TTR 19 0.70 X ^(a)Ratio of the protein concentrations from HIV-infected patients with HL versus HIV-infected patients without HL. ^(b)An “X” indicates that IPA lists these tissues or cell types as a known source of these proteins. There are commonly other tissues or cellular sources for these proteins that are not included in this table. ^(c)WBC, white blood cells. ^(d)IR, inflammatory response. 

We claim:
 1. A biomarker for detecting lymphoma in a person, comprising at least one protein listed in Table S3.
 2. The biomarker of claim 1 wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.
 3. The biomarker of claim 1 wherein the at least one protein is found in plasma.
 4. The biomarker of claim 1 wherein the person is a high-risk subject.
 5. A method of detecting lymphoma in a person, comprising: a. obtaining a plasma sample from the person; b. measuring the level of at least one protein listed in Table S3 in the plasma sample; c. comparing the level of the at least one protein in the plasma sample with the level in a normal or healthy subject; and d. diagnosing the lymphoma based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.
 6. The method of claim 5 wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.
 7. The method of claim 5 wherein the person is a high-risk subject.
 8. The method of claim 5 wherein the obtaining a plasma sample from the person further comprises providing a reagent that reacts with proteins in the plasma sample to detect the presence of lymphoma.
 9. The method of claim 8 wherein the reagent is an antibody.
 10. A test kit for diagnosing lymphoma in a person comprising: a. an antibody-based assay that measures a plurality of plasma biomarkers selected from the group consisting of the biomarkers of Table S3; and b. instructions for conducting the antibody-based assay.
 11. The test kit of claim 10 wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.
 12. The test kit of claim 10 wherein the person is a high-risk subject.
 13. A diagnostic system for detecting the presence of lymphoma in a person, the system comprising: a. a plurality of protein assays measuring a plurality of plasma biomarkers, wherein the plasma biomarkers are selected from the biomarkers of Table S3, wherein concentration levels or peak intensity values of at least one of the plasma biomarkers is modified by the presence of the lymphoma in the person; and b. a detector for detecting the plasma biomarkers.
 14. The diagnostic system of claim 13 wherein the detector is a mass spectrometer.
 15. The diagnostic system of claim 13 wherein the detector comprises at least one labeled antibody specific for a biomarker of Table S3.
 16. A method of monitoring tumor response to treatment in a lymphoma patient, comprising: a. obtaining a baseline plasma sample from the patient; b. measuring the level of at least one protein listed in Table S3 in the baseline plasma sample; c. administering therapy to the patient; d. thereafter obtaining a second plasma sample from the patient; e. measuring the level in the second plasma sample; and f. comparing the levels; wherein a changed level after treatment indicates a therapeutic response.
 17. The method of claim 16 wherein the therapy is chemotherapy or radiation therapy.
 18. The method of claim 16 wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.
 19. A method of monitoring patient compliance with a drug treatment protocol, comprising: a. obtaining a plasma sample from the patient; b. measuring the level of at least one protein listed in Table S3 in the sample; and c. determining if the level is increased in the patient sample compared to the level in a control untreated sample; wherein a change in protein concentration indicates patient compliance with the drug treatment protocol. 